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Abstract 
English version 
 
Endothelial Lipase (EL) is the most recently identified member of the plasma 
triglyceride lipase family. EL has a higher specificity for Phospholipids (PL) 
compared to triglycerides (TG) and has been shown to be a major regulator of 
HDL-C levels both in vitro and in vivo. More recent data showed that EL also 
promotes the catabolism of apoB-containing lipoproteins. In humans, genetic 
variants for EL are associated with increased HDL-C levels but these changes 
do not translate into a reduction in cardiovascular disease risk. Early clinical 
studies demonstrated a strong correlation between EL mass and several traits 
of metabolic syndrome such as body mass index (BMI), visceral adiposity, 
inflammation, insulin resistance and atherogenic lipoprotein levels. The causal 
relationship linking EL to one of multiple of these traits is still unknown. To 
date, whether increased EL levels may be causal to the observed phenotype 
or a secondary outcome has not been established. 
The aim of this thesis is to assess the role of EL in TG-rich lipoprotein (TRL) 
metabolism and to investigate the relationship between EL activity, hepatic 
lipid metabolism and the development of key traits of metabolic syndrome in 
vivo. In order to compare the onset and severity of metabolic syndrome traits 
in the presence or absence of EL activity, WT and EL deficient mice (EL-KO) 
were chronically fed a high fat diet. Results demonstrated that EL deficient 
mice gained significantly more weight and they developed a more severe 
glucose intolerance and meta-inflammatory state. The appearance of these 
traits was accompanied by a severe dyslipidemia that was once again more 
pronounced in EL-KO mice, compared to WT. The most evident difference 
between EL-deficient mice and control group was the disproportioned diet-
induced increase in TG. This phenotype originated from accumulation of post-
prandial TG-rich lipoproteins. In vivo kinetic experiments demonstrated that 
the lipolytic clearance of TG-labeled TRL was significantly impaired in EL-KO 
mice without any effect on TG secretion. The in vitro determination of EL 
activity towards radiolabeled-TRLs suggested that EL may function as a 
Lipoprotein Lipase (LPL) activity enhancer. As a consequence, EL may have 
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a major role in reducing TG levels during postprandial hyperlipemia and this 
effect may be mediated by both direct lipolysis and facilitation of LPL.  
Finally, the assessment of liver function revealed that the dietary treatment 
induced severe steatosis in EL-KO mice. Consistent with reduced lipolysis, 
the TG-derived FA uptake was impaired in EL-KO mice and this was 
associated with the upregulation of lipogenic genes and the development of 
abnormalities in the FA composition.  
In conclusion, data from this thesis support a model by which EL is required 
for efficient triglyceride-rich lipoprotein clearance and the absence of this 
function impairs hepatic fat intake and results in compensatory de novo 
lipogenesis, which may contribute to systemic obesity and insulin resistance. 
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Abstract 
Versione in Lingua Italiana 
 
La Lipasi Endoteliale (EL) è l’ultimo membro identificato della famiglia delle 
lipasi plasmatiche dei trigliceridi (plasma triglyceride lipase). EL ha una 
maggior specificità per i fosfolipidi (PL) che trigliceridi (TG) ed è un enzima 
chiave nella regolazione dei livelli di HDL sia in vitro che in vivo. Studi più 
recenti hanno indicato che EL è in anche grado di promuovere il catabolismo 
delle lipoproteine contenenti apoB. Nell’uomo, varianti nel gene che codifica 
per EL, sono state associate a più elevati livelli di colesterolo HDL ma 
sorprendentemente ciò non si traduce in un ridotto rischio cardiovascolare. 
Studi clinici hanno evidenziato che la concentrazione e attività di EL sono 
positivamente associate alla severità dei tratti tipici della sindrome metabolica 
come indice di massa corporea, obesità centrale, infiammazione, insulino 
resistenza e profilo lipoproteico più aterogenico. Quale sia il nesso causale di 
questa associazione non è noto e ad oggi non è possibile stabilire se elevati 
livelli di EL siano alla base dell’eziologia del profilo osservato o se, al 
contrario, siano un tratto secondario.  
Scopo di questa tesi è di stabilire quale sia il ruolo di EL nel metabolismo 
delle lipoproteine ricche in trigliceridi (TRL) e di investigare la relazione tra 
attività di EL, metabolismo lipidico epatico e sviluppo dei tratti caratteristici 
della sindrome metabolica in vivo.  Al fine di poter comparare non solo la 
severità ma anche il tempo di insorgenza della sindrome metabolica, in 
presenza o assenza di EL, sono stati utilizzati topi controllo (wild type, WT) e 
topi con deficit di EL (EL-KO), sottoposti ad una dieta ricca di grassi a lungo 
termine. I risultati hanno dimostrato che i topi EL-KO accumulano 
significativamente più peso rispetto ai WT, sviluppano una più severa 
intolleranza al glucosio, e uno stato metainfiammatorio. La comparsa di questi 
tratti è accompagnata da una severa dislipidemia, ancora una volta più 
marcata nei topi EL-KO rispetto ai WT. La differenza più significativa, tuttavia, 
è lo sproporzionato aumento dei livelli di TG in risposta alla dieta. All’origine di 
questo fenotipo vi è l’accumulo di lipoproteine post-prandiali ricche di TG. 
Esperimenti cinetici in vivo hanno dimostrato che la clearance di TRL 
radiomarcate è molto ridotta nei topi EL-KO e questo fenomeno è dovuto a 
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una ridotta lipolisi, mentre la secrezione epatica di TG non è affetta. Quando 
l’attività di EL nei confronti delle TRL marcate è stata testata in vitro, è emerso 
che EL potrebbe fungere da facilitatore dell’attività della lipasi lipoproteica 
(LPL). Di conseguenza, EL potrebbe rivestire un ruolo importante nel ridurre I 
livelli di TG nel contesto dell’iperlipemia postprandiale e questo effetto 
potrebbe essere mediato sia da un’attività lipolitica diretta, sia dalla 
facilitazione dell’attività lipolitica di LPL. Infine, la valutazione della funzionalità 
epatica ha rivelato che i topi EL-KO sviluppano una franca steatosi. La 
capacità del fegato di captare gli acidi grassi derivanti dai TG, è ridotta nei 
topi con deficit di EL ed è stato osservato un parallelo aumento dei livelli di 
espressione di geni coinvolti nella lipogenesi e una drammatica alterazione 
del contenuto di acidi grassi.  
In conclusione, i dati raccolti in questa tesi supportano l’ipotesi che EL sia 
essenziale per un’efficiente clearance delle TRL e, in sua assenza, via sia un 
ridotto flusso di acidi grassi al fegato. Ciò indurrebbe un aumento 
compensatorio della lipogenesi e potrebbe ulteriormente contribuire 
all’insorgenza di obesità e insulino resistenza. 
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1 Plasma Lipases: at the crossroads between 
lipoprotein and tissue lipid metabolism 
 
The Triglyceride lipase gene family includes several genes that share a high 
degree of homology (LIPC,LIPG, LPL, PS-PLA1, LIPH, PLRP-2, PL, PLRP-1) 
[1]. Although the cell expression pattern and the substrate specificity highly 
differ among the different members, all the enzymes are able to hydrolyze 
ester bonds of hydrophobic lipids [1]. The function of each member and 
impact on the overall physiology is highly dependent on the site of expression. 
Three of the cited genes, LIPC, LIPG and LPL, encode enzymes that function 
in the plasma (Hepatic Lipase, Endothelial Lipase and Lipoprotein lipase, 
respectively) and catalyze the hydrolysis of lipids on circulating lipoproteins [2-
4]. The released fatty acids are then available for uptake by peripheral tissues 
where they can exert trophic or modulatory functions. As a result, plasma 
lipase activities affect not only the lipoprotein metabolism but also determine 
the availability of Free Fatty Acids (FFA) in peripheral tissues thus influencing 
systemic lipid homeostasis. 
1.1 Overview of Plasma Lipoprotein Metabolism 
 
Lipoproteins are heterogeneous lipid-protein complexes. They exert several 
functions including the transport of hydrophobic lipids through the circulation 
[5]. The two more clinically relevant non-polar lipids are cholesterol and 
Triglycerides (TG) [6]. Epidemiological evidence, in fact, has associated the 
levels of different plasma lipids and lipoproteins with the risk of developing 
Cardiovascular Disease (CVD)[5].  
Physiologically, cholesterol is an essential component of lipid membranes, 
and plays a major role in the synthesis of steroid hormones, bile acids, and 
vitamin D [7]. The cholesterol membrane content affects the properties of cell 
membranes including fluidity and depolarization capacity [8]. The major 
sources of cholesterol are endogenous synthesis and exogenous uptake from 
the diet. The first pathway is quantitatively more relevant (~80% of total 
circulating cholesterol) [9, 10].  
TG are macromolecules containing three fatty acid (FA) molecules esterified 
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to a glycerol backbone. TG represents the main source of energy for 
peripheral tissues and the main energy storage form for adipose tissue [9].  
Plasma lipoprotein classification 
 
After ex novo synthesis or absorption from dietary source, cholesterol and TG 
are incorporated in macromolecular complexes named lipoproteins. 
Lipoproteins are composed of highly hydrophobic lipid cores containing non-
polar lipids (mainly TG and esterified cholesterol, CE) and an outer layer 
containing polar phospholipids, non-esterified cholesterol (UC) and several 
apolipoproteins. Lipoproteins represent the vehicle through which different 
lipid species can be delivered to and taken up by target tissues. Lipoproteins 
are extremely heterogeneous in size, shape, lipid and apolipoprotein 
composition. Several classification methods have been suggested, that 
highlight the different peculiarities of these macromolecules. The clinically 
most accepted classification methods distinguish lipoproteins based on their 
surface charge (electrophoretic mobility) and density. Based on these criteria 
lipoproteins can be classified into five categories: chylomicrons (CM), very-
low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL) low-
density lipoproteins (LDL) and high-density lipoprotein (HDL) (Table I-1) [11].   
Lipoprotein Density (g/mL) Size (nm) 
Electrophoretic 
mobility 
Chylomicrons (CM) <0.93 75-1200 origin 
VLDL 0.93-1.006 30-80 pre-β 
IDL 1.006-1.019 25-35 β 
LDL 1.019-1.063 18-25 β 
HDL 1.063-1.210 5-12 α 
 
Table I-1 Classification of the major human plasma lipoproteins  
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Plasma lipoprotein composition 
 
Plasma lipoproteins are characterized by a very different lipid and protein 
composition, that affects their physical and chemical properties and influences 
their ability to interact with specific receptors (table I-2).  
Chylomicrons 
 
Chylomicrons are large, TG-rich lipoproteins secreted by the intestine. Given 
their large size and high TG content, CM are characterized by a very low 
density (<0.93 g/mL). They are responsible for the transport of diet-derived 
cholesterol and TG to peripheral tissues. CM contain a variety of 
apolipoproteins (A-I, A-II, A-IV, A-V, B48, C-II, C-III, E) [12]. The structurally 
more relevant apolipoprotein is apoB-48, which is secreted by enterocytes at 
a ratio of 1:1 molecule of CM [12]. After being released in the circulation CM 
undergo an extensive remodeling by peripheral cells. The interaction between 
apoC-II and lipolytic enzymes such as Lipoprotein Lipase (LPL) leads to the 
hydrolysis of TG and release of free fatty acids [2]. FFA can then be taken up 
by peripheral cells through membrane transporters. The removal of TG from 
CM results in the formation of smaller particles, that progressively acquire 
Cholesterol Esters and apoE from circulating HDL. The resulting lipoproteins 
are characterized by a wide compositional and density range and they are 
collectively named Chylomicron Remnants.   
Very-Low Density Lipoproteins 
 
VLDL are TG rich lipoproteins produced by the liver. They are characterized 
by very low density (table I-1) and a relatively low protein content (8-10%). 
Their main protein constituent is apoB-100 but they also contain apoE and C-
peptides. VLDL are synthesized by the liver through the activity of microsomal 
triglyceride transfer protein (MTP) [12, 13]. MTP catalyzes the assembling of 
apoB-100 with endogenous TG. This initial core can be further enriched with 
apoE and C-peptides [13]. The main function of VLDL is to transport 
endogenous TG from the liver to peripheral cells, where they can be depleted 
of TG and remodeled into Intermediate Density Lipoproteins (IDL). 
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Intermediate-Density lipoproteins 
 
IDL are lipoproteins with a density range of 1.006-1.1019 g/mL. They have a 
very short half-life and in healthy subjects their concentration is normally very 
low. They result from the partial catabolism of VLDL. They undergo further 
remodeling, that leads to the formation of LDL. This process is associated 
with the activity of Hepatic Lipase (HL) and hepatic triglyceride hydrolase (H-
TGL) [3]. IDL can be taken up by the liver through the LDL receptor-related-
protein (LRP) or LDL receptor (LDL-R). 
Low Density Lipoproteins 
 
LDL are lipoproteins with a hydrated density of 1.019-1.063 g/mL and a 
particle size of 20-30 nm. They contain ~20% and 80 % of protein and lipids, 
respectively. The lipid core is enriched in Cholesterol esters whereas the main 
protein component is apoB-100 (1:1 molecule:particle). ApoB-100 is the 
ligand for the LDL-R, a receptor highly expressed on the membrane of 
hepatocytes and other cell types [13].  
High Density Lipoproteins 
 
HDL are an heterogeneous class of lipoproteins. They are believed to have 
several functions including antioxidant, ant-inflammatory and anti-thrombotic 
properties [14]. Traditionally they are believed to play a key role in the 
Reverse Cholesterol Transport, the process by which excess cholesterol is 
transported from peripheral cells to the liver for excretion in the bile [15]. HDL 
particles are enriched with cholesterol and phospholipids. They contain 
several different apolipoproteins including apoA-I, A-II, A-IV, C-I, C-II, C-III 
and apo-E. ApoA-I is responsible for the structural stabilization of the core and 
it is secreted by liver and intestine in the very early phases of HDL generation 
[16].  
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Lipoprotein CM VLDL IDL LDL HDL 
Triglycerides  
(%) 
80-95 45-65 15-35 4-8 2-7 
Phospholipids 
(%) 
3-6 15-20 25-30 18-24 26-32 
Free Cholesterol 
(%) 
1-3 4-8 6-8 6-8 3-5 
Esterified 
Cholesterol 
(%) 
2-4 16-22 18-30 45-50 15-20 
Proteins 
(%) 
1-2 6-10 15-20 18-22 45-55 
Major 
apolipoproteins 
A-I, A-IV, B, 
C-I, C-III, E 
B, E, C-I, C-
II, C-III 
B, E B A-I, A-II, E 
 
Table I-2 Lipid and apolipoprotein composition of major plasma lipoproteins   
 
Pathways of plasma lipoprotein metabolism 
 
Lipoprotein metabolism is traditionally described as an exogenous pathway, 
endogenous pathway and reverse cholesterol transport. The exogenous 
pathway is the process by which lipids from dietary source are transported 
from the intestine to the liver. The endogenous pathway is the pathway of 
transport of de-novo synthesized lipids from hepatocytes to peripheral cells. 
Finally, the reverse cholesterol transport is the retrograde transport of 
cholesterol in excess from peripheral cells to the liver (Figure I-1).  
 
 
The exogenous pathway 
 
In the fed state, lipids from the diet are absorbed by the intestinal cells. 
Dietary TG are hydrolyzed by pancreatic and intestinal lipases in the 
gastrointestinal tract so that enterocytes mainly absorb them in the form of 
FFA and monoacylglycerol.  Cholesterol, in turn is absorbed in the esterified 
form and hydrolyzed into UC and FFA in the enterocyte.  FFA, MAG and UC 
are re-esterified into TG and assembled with apoB-48. This process is 
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catalyzed by the microsomal triglyceride transfer protein (MTTP) and it is the 
key step in CM formation [17]. CM are released in the lymphatic system and 
from there to plasma. As soon as they reach the vascular compartment CM 
interact with lipases facing the vascular lumen. Lipases, in particular 
Lipoprotein Lipase (LPL), extensively hydrolyze TG and release FFA that can 
be taken up by peripheral tissues such as muscle and adipose tissue via FA 
transporters (eg Fatty acid transport proteins, FATPs and  CD36) [2, 18].  
Intracellularly FFA can undergo oxidation or re-esterification. As a 
consequence of TG hydrolysis, CM become smaller in size, progressively 
acquire CE and apoE and, in turn they transfer apoA and C peptides to HDL. 
The resulting particles are named CM remnants and they can be cleared by 
the liver via LDL-R, LRP and syndecan-4 receptor pathways. The binding is 
mediated by apoE and leads to the internalization of the whole remnant 
particle [19, 20]. 
The endogenous pathway 
 
The first step in the endogenous pathway is the formation of VLDL particles. 
Hepatocytes assemble TG into VLDL on apoB-100 backbone and then 
secrete them into plasma [13]. This process is mediated by MTP and it is 
highly dependent on the intracellular TG availability. After secretion, VLDL 
particles are transported to peripheral tissues where, similar to CM, the TG is 
hydrolyzed by vascular lipases, in particular LPL. This process leads to the 
formation of IDL [2]. IDL are relatively more enriched in apoE and CE and can 
be partially taken up by the liver. The majority of IDL, anyway undergo further 
metabolism, leading to the formation of LDL. Hepatic lipase (HL) progressively 
hydrolyzes TG in IDL and this process is accompanied by the transfer of most 
of the exchangeable apolipoproteins to other particles [21]. The result is the 
generation of LDL particles, characterized by a CE core and mainly containing 
apoB-100. 
LDL metabolism is highly dependent on intracellular cholesterol trafficking and 
plasma transport. These two components determine the overall balance 
between LDL formation from TG-rich lipoproteins and LDL clearance.  
Approximatively 70 % of the LDL particles are cleared by LDL-R in the liver 
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[22]. LDL-R is activated by apoB-100 and apoE and promotes the endocytosis 
of LDL. The levels of active LDL receptor are regulated by the intracellular 
cholesterol content through different pathways at a transcriptional and post-
transcriptional level [22]. One mechanism involves the activation of SREBP 
(Sterol regulatory Element Binding Protein) transcription factors. When 
cholesterol levels are low, SREBs are cleaved and translocated from the 
endoplasmic reticulum to the nucleus, where they actively promote the 
transcription of LDL-R and HMG-CoA reductase, the key enzyme in de-novo 
cholesterol synthesis [23]. On the other hand, when cholesterol levels are 
high SREBPs are inactive and oxidized products of cholesterol metabolism 
stimulate the activation of Liver X Receptors (LXRs). LXRs promote the 
expression of IDOL (inducible degrader of the LDLR), a E3-ubiquitin ligase 
that induces ubiquitination and degradation of the LDLR [24]. Finally, a 
recently discovered post-transcriptional regulatory mechanism involves 
PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is a secreted 
protein that binds to the extracellular domain of LDL-R and triggers its 
translocation to the lysosomes [25]. 
Reverse Cholesterol transport 
 
The HDL-mediated removal of cholesterol from peripheral cells and its 
transport to the liver for excretion through the bile is named reverse 
cholesterol transport (RCT). Since the accumulation of cholesterol in the 
arterial wall and arterial macrophages is believed to be a key step in the 
development of atherosclerosis, RCT is considered an anti-atherogenic 
process [26].  
Nascent discoidal HDL are secreted by liver and intestine in an ABCA1-
dependent fashion. This process consists of the synthesis of apoA-I that is 
readily lipidated with phospholipids and free cholesterol. These lipid-poor 
particles can acquire free cholesterol from other peripheral cells through a 
process named cell cholesterol efflux [27].  After secretion, small HDL 
particles are further remodeled by several enzymes and transfer proteins.  
A key enzyme in HDL maturation is Lecithin:Cholesterol Acyl Transferase 
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(LCAT), which is responsible for the esterification of cholesterol in plasma. Its 
preferred substrate is HDL and it uses apoA-I as cofactor [28, 29]. As result 
LCAT promotes the transition of HDL from small poorly lipidated particles to 
spherical CE enriched lipoproteins. Mature HDL can interact with Cholesteryl 
Ester Transfer Protein (CETP), that promotes the exchange of CE and TG 
from HDL and TG-rich lipoproteins, respectively [29].  
Furthermore, Phospholipid Transfer Protein (PLTP) promotes the exchange of 
surface components (phospholipids, cholesterol and apolipoproteins) from 
triglyceride-rich lipoproteins to HDL [29].  
The TG-rich HDL particles can be hydrolyzed by lipases (LPL, HL and 
endothelial lipase, EL) in the vascular compartment. This process destabilizes 
the HDL structure, leading to conversion of mature particles into small 
particles [16]. During this process, the apolipoprotein component, and notably 
apoA-I, can be released in plasma in a very poorly lipidated or free form. 
These small particles are then cleared by the kidney.  CE-rich HDL, finally can 
be taken up by hepatocytes via Scavenger receptor class B member 1 (SR-
BI) [29].  
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Figure I-1 Schematic of plasma lipoprotein metabolism 
 
Lipids from dietary source are absorbed by the intestine and hydrolyzed into 
FA and cholesterol. They are then re-esterified into TG and CE and packed 
into chylomicrons with apoB48 by MTTP. Chylomicrons are firstly secreted 
into the lymph and then released into the blood stream. CM-associated TG 
are hydrolyzed by LPL thus providing FFA for peripheral cells. In adipocytes, 
TG are re-synthesized by acyl CoA:diacylglycerol acyltransferase (DGAT) for 
energy storage. During fasting TG can be hydrolyzed by adipose TG lipase 
(ATGL) and hormone sensitive lipase (HSL). Chylomicron remnants (CMRs) 
are internalized into the liver by LRP1. In the liver triglycerides and cholesterol 
(either taken up from the circulation or synthesized ex-novo) are combined 
with apoB100 to form VLDL particles. VLDL are secreted into the circulation 
where their TG can be hydrolyzed by LPL. This process is accompanied by 
the remodeling of VLDL into IDL. IDL are hydrolyzed by hepatic lipase (HL) 
thus generating LDL particles. LDL deliver cholesterol to the peripheral 
tissues and they are finally cleared from the circulation via LDLR pathway. 
The retrograde transport of cholesterol from peripheral cells to the liver is 
mediated by HDL. HDL are generated in the liver in an ABCA-dependent 
fashion. HDL interact with ATP-binding cassette A1 (ABCA1) and ABCG1 
transporters located at the membrane of peripheral cells, thus promoting the 
efflux of cholesterol. HDL are further remodeled by LCAT and CETP. This 
process leads to the formation of mature CE enriched particles that can 
interact with EL and SR-BI. EL promotes the hydrolysis of HDL-PL thus 
generating smaller particles that can further acquire lipids whereas SR-BI 
catalyzes the selective uptake of HDL-CE.  
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1.2 Tissue Fatty acid metabolism 
 
Peripheral tissues use lipoprotein-associated TG as source of FA for -
oxidation and for long term energy-storage. These two processes are highly 
regulated and their relative utilization depends on the features of the tissue 
and on the metabolic state (fasted vs fed conditions)[30]. Three organs are 
capable of storing TG and hydrolyzing them to release FA: adipose tissue, 
skeletal muscle and the liver. In fed conditions, dietary TG is absorbed by the 
intestine and released in the circulation in CMs [30]. CM deliver TG to 
peripheral tissues where it can be hydrolyzed into FFA. The quantitatively 
more relevant hydrolysis process happens in tissues that express Lipoprotein 
Lipase (LPL) [31]. In the postprandial state, there is a high availability of 
nutrients from the diet that exceeds the tissue energetic needs. In this phase, 
LPL expression is highly increased in the adipose tissue [2]. LPL hydrolyzes 
TG and releases FA that are mainly taken up by adipocytes, where they can 
be re-esterified and stored in the form of TG. In these conditions hepatocytes 
respond to the insulin stimulation by down-regulating the production of VLDL. 
During fasting conditions, on contrary, the adipose tissue actively hydrolyses 
TG and release FFAs that are transported in complex with albumin and serve 
as substrates for -oxidation in skeletal and heart muscles [30]. At the same 
time, the liver synthesizes VLDL that can provide an additional source of TG 
and FA to peripheral tissues.  
 
Liver 
 
The healthy liver contains typically 1-10% of fat by weight. The lipid sources in 
the liver are TG from CM remnants and FFA derived from peripheral lipolysis 
(mainly occurring in the adipose tissue during the fasting state). In 
physiological conditions, the adult liver does not express LPL but expresses 
high levels of Hepatic lipase (HL) [32].  HL has higher affinity for smaller 
particles (such as IDL, LDL and HDL) and shows a mixed TG and 
Phospholipid lipase activity [33].  
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Mechanisms of FA uptake 
 
The uptake of released FFA is mediated by membrane transporters. The main 
FFA transporters are: FA Transport Protein (FATP), CD36, Caveolins, and 
FA-Binding Protein (FABP) [34]. 
FATP  
 
FATP exists in 6 different isoforms [35]. All of the different variants share a 
common motif and fatty acylCoA synthase function. The two most abundant 
isoforms in the liver are FATP2 and FATP5, which are responsible for the 
translocation and activation of FA [36, 37]. The result of FATP activity is the 
activation of incoming FA through the conversion to CoA thioesters. These 
derivatives are thus available for further metabolism. 
CD36  
FAT/CD36 (fatty acid translocase / cluster of differentiation 36), is an integral 
membrane protein that binds different ligands including lipoproteins 
phospholipids and long chain fatty acids. CD36 has been isolated in several 
cell types including macrophages, adipocytes, myocytes, enterocytes, and 
hepatocytes. CD36 is one of the best characterized FA transporters. The 
regulation of CD36 activity is this dependent on its translocation from 
intracellular compartments to the plasma membrane [38]. This process is 
promoted by insulin signaling and by the activation of other transcription 
factors such as Forkhead box protein O1 (FoxO1) [31]. Several transcription 
factors have been directly associated with increased CD36 expression (liver X 
receptor, LXR, pregnane X receptor, and PPARγ) [31]. 
Caveolins  
The Caveolin family comprises three membrane integral proteins named 
Caveolin 1, 2, and 3 [39]. They are located in the caveolae, membrane 
regions characterized by a particular lipid composition and enriched in 
certainproteins. Caveolins have been associated with receptor-independent 
endocytosis of several molecules [39]. Through this process caveolins are 
believed to promote the uptake of TG and FA from the circulation. Although 
the mechanism has not been fully clarified, Caveolin 1 knockout mice 
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exhibited a reduced TG accumulation in the liver [40]. 
FABPs 
FABPs are an heterogeneous group of proteins that bind lipophilic ligands 
including FA [41]. Among the different isoforms FABP4 and 5 are highly 
expressed in adipocytes and macrophages and to a lesser extent hepatocytes 
[41]. FABPs are located in cellular membranes where they promote the 
transport of FA to specific cellular organelles (nucleus, mitochondrion, 
endoplasmic reticulum and lipid droplets). Depending on the localization 
FABPs can promote either -oxidation (e.g. mitochondrion) or lipid storage 
(e.g lipid droplets) [42, 43]. The physiological relevance of FABP4 in the liver 
is unclear but it has been reported a positive association between FABP4 
levels and Non-Alcoholic Fatty Liver disease (NAFLD) [44].  The expression of 
FABPs is under the control of of PPAR  and it is positively regulated by insulin 
signaling.  
De novo Lipogenesis 
 
In addition to the ability to take up circulating TG-rich lipoproteins, hepatic 
cells can synthetize FA ex novo from glucose and other carbohydrate 
precursors [45, 46]. This process, named de novo Lipogenesis (DNL) consists 
of the synthesis of FA from acetyl-CoA subunits. The resulting FA can then be 
esterified to the glycerol backbone thus generating TG [47](Figure I-2).  
The first step in the DNL is the production of acetyl-CoA from citrate. This step 
is catalyzed by ATP-citrate lyase (ACL) [48]. AcCo-A is then converted to 
malonyl-CoA by acetyl CoA carboxylase (ACC) [49]. 
The newly formed malonyl-CoA can be condensated with acetyl-coA in a 
reaction catalyzed by fatty acid synthase (FAS). This multifunctional cytosolic 
protein homodimerizes into the active form and catalyzes the elongation of the 
nascent FA by multiples of two carbons. The final product of FAS activity is 
typically palmitate (C16:0) [50].  
Fatty acids derived from the FAS reaction can be further elongated and 
desaturated by other enzymes all located in the endoplasmic reticulum. Fatty 
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acid elongation is catalyzed by Elovl family members (elongation of very long-
chain fatty acid) [51]. There are 7 Elovl isoforms, with different tissue and 
substrate specificity [51]. Elovl6 is believed to be the main player in the 
hepatic elongation of fatty acids. The most common substrates are fatty acids 
consisting of 12, 14 or 16 carbons that derive from the FAS activity or are 
absorbed from the diet. The further desaturation of FA is mediated by 
Stearoyl-CoA desaturases (SCDs) [52].  Their activity introduces a single 
desaturation in Δ9 position of saturated fatty acids. Although seven isoforms 
of SCDs have been identified, SCD-1 is the most abundant in liver and 
adipose tissue [52]. 
Regulation of De novo Lipogenesis 
 
De novo lipogenesis is a process regulated at multiple levels. In the 
postprandial phase, higher levels of insulin activate the transcription factors 
LXR (liver X Receptor), and SREBP1c (sterol regulatory element-binding 
protein 1c) [23, 46]. At the same time, increasing intracellular levels of glucose 
activate the carbohydrate-responsive element- binding protein (ChREBP) [46]. 
These transcription factors altogether are responsible for the promotion of 
glycolyisis, activation of Krebs cycle, and lipogenesis.  
Another family of transcriptions factors highly involved in the regulation of 
insulin metabolism and FA utilization is peroxisome proliferator-activated 
receptors (PPARs). PPAR  is the master regulator of de novo lipogenesis 
whereas PPAR  exerts opposite functions, inducing and increase in FA 
utilization via -oxidation [53-55].  
LXR 
The liver X receptors (LXRα and LXR β) are ligand-activated nuclear 
transcription factors. LXR  is mainly expressed in the liver, adipose tissue, 
and intestine, whereas LXR  is ubiquitous [56, 57].  
Their natural ligands are oxysterols and other cholesterol metabolites. 
Physiologically LXRs act as sensors for cholesterol overload and promote the 
transcription of genes involved in intestinal cholesterol absorption, reverse 
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cholesterol transport, bile acids synthesis and glucose metabolism [56].  LXR 
is able to increase the expression of genes involved in HDL lipidation and 
reverse cholesterol transport such as ABCA1, ABCG1, ABCG5, ABCG8, 
apoE and PLTP [56,59]. On the other hand, LXR activation upregulates the 
expression of SREBP1c, leading to an increase in fatty acid synthesis and TG 
plasma secretion [58, 59]. 
SREBPs 
SREBPs are a family of transcription factors that promote the activation of 
enzymes required for the synthesis of cholesterol, FA, TG and phospholipids 
[23]. SREBPs are firstly synthesized in the Endoplasmic reticulum as 
precursors [23]. When activated, SREBPs are progressively cleaved and the 
nuclear form of SREBP is translocated into the nucleus where it promotes the 
transcription of its target genes [60-64]. Three different SREBP proteins have 
been isolated in humans. SREBP-1a and 1c (encoded by the SREBF-1 gene) 
and SREBP-2 (encoded by SREBF-2). SREBP-1c isoform is highly expressed 
in liver, adipose tissue and skeletal muscle, whereas SREBP-1a is 
predominant in intestinal cells [65]. Different SREBP family members are able 
to activate the same genes, indicating a high degree of redundancy in the 
function of these transcription factors. Nevertheless, SREBP-1a seems to be 
more selective in inducing the expression of genes involved in cholesterol and 
FA synthesis (HMG-CoA synthase, HMG-CoA reductase, ACC, FAS, SCD-1) 
whereas SREBP-1c seems to be more selective for lipogenic genes [23].  At 
the transcriptional level, SREBP1c transcription is induced by insulin and 
LXRα [23]. When activated, SREBP1c promotes transcription of selected 
target genes that include ACC, FAS, and SCD1. The overall results of 
SREBP1c activation is thus de novo lipogenesis.   
ChREBP 
The carbohydrate-responsive element- binding protein (ChREBP) is a 
transcription factor activated by  increasing intracellular glucose levels [66]. 
Several glycolysis intermediates are able to promote ChREBP activation. 
Activated ChREBP translocates into the nucleus where it binds Carbohydrate 
response elements (ChoRE) and promotes the transcription of selected genes 
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including pyruvate kinase, FAS, ACC and SCD1 [66, 67].  
PPARs 
PPARs are ligand-inducible transcription factors [68]. Three PPARs have 
been isolated in mammalian cells: PPARα , PPARδ and PPARγ [68]. PPARs 
are mainly activated by binding with dietary fatty acids. Upon activation, 
PPARs heterodimerize with retinoid X receptor (RXR) and bind to PPAR-
responsive regulatory elements. These events trigger the expression of genes 
involved in adipogenesis and lipid metabolism.  
Different PPAR isoforms have specific functions and their activation results in 
different metabolic processes. PPARα, the first PPAR to be identified, is 
expressed predominantly in the liver, heart and brown adipose tissue (BAT) 
and is the main promoter of fatty acid oxidation [69].  PPARδ is ubiquitously 
expressed. Its function is similar to that of PPARα but its higher abundance in 
the skeletal muscle, liver and heart confers it a primary role in the metabolic 
homeostasis of those tissues [70].  PPARγ is highly expressed in white 
adipose tissue (WAT) and BAT, where it is a master regulator of adipogenesis 
as well as a potent modulator of whole-body lipid metabolism and insulin 
sensitivity [71, 72]. 
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Figure I-2 Regulation of de novo lipogenesis in the liver by ChREBP, 
SREBP1c and LXR.  
 
In the postprandial state, insulin plasma levels increase. Insulin binding to its 
receptor promotes the translocation and activation of liver X receptors (LXR). 
LXR induces the transcription of lipogenic genes including sterol regulatory 
element binding protein 1c (SREBP1c) and carbohydrate-responsive element- 
binding protein (ChREBP). The activation of these regulatory genes promotes 
the transcription of lipogenic genes including acetyl CoA carboxylase (ACC), 
fatty acid synthase (FAS), elongation of long-chain fatty acids family member 
6 (ELOVL6) stearoyl-CoA desaturase 1 (SCD1). In addition to these genes, 
ChREBP induces the expression of pyruvate kinase, a key gene in the shift of 
glycolysis products into the Krebs cycle.  
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Adipose Tissue  
 
The adipose tissue represents the main TG storage compartment in the 
human body. On average, 30% and 20% of the body weight in women and 
men respectively is fat [30]. The source of fat in adipocytes is mainly the 
uptake of dietary-derived TG while only a minor fraction of TG is derived from 
de novo lipogenesis. In the fed state LPL is synthesized in the adipocyte and 
it is translocated to the luminal side of endothelial cells [2]. Secreted LPL is 
bound to proteoglycans at the endothelial cell surface and represents the 
active fraction of total LPL [73]. A consistent fraction of synthesized LPL 
doesn’t enter the secretory pathway but gets degraded intracellularly [73, 74]. 
The balance between degraded and secreted LPL varies with the metabolic 
state and represents one of the main regulatory mechanisms of TG utilization 
in the adipose tissue [31, 73]. The FA derived from LPL hydrolysis reach the 
adipocyte through a mechanism involving specific transporters such as Fatty 
Acid Translocases (mainly CD36) and Fatty Acid Binding Proteins (mainly 
FABP1) [31].  
The mobilization of TG from adipose tissue storage is a tightly regulated 
mechanism. During starvation and stress the levels of circulating 
catecholamines increase thus activating -adrenoreceptors located on 
adipocyte cell membrane [30]. This triggers a cascade of events that lead to 
the activation of three key lipases: adipose triglyceride lipase (ATGL), 
hormone-sensitive lipase (HSL) and Monoacylglycerol lipase (MGL)[75]. The 
concerted activity of these three enzymes promotes the complete hydrolysis 
of TG into glycerol and three 3 FA chains. ATGL is the first enzyme in this 
process and it is responsible for the conversion of most TG into DAG in 
human adipocytes. ATGL requires the presence of its coactivator, CGI-58 
(comparative gene identification-58)[75]. The second enzyme is HSL. The 
regulation of HSL activity is dependent on its phosphorylation status. -
adrenergic stimulation induces a sudden and marked increase in cAMP [76]. 
This in turn activates Protein Kinase A that actively phosphorylates HSL and 
promotes the translocation of HSL to the surface of the lipid droplets. Here 
HSL actively interacts with phosphorylated perilipin-1 [75, 76]. In the fully 
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phosphorylated status HSL is able to hydrolyze TG and DAG into MAG. The 
final step of TG hydrolysis is the conversion of MAG into Glycerol and FA, 
catalyzed by MGL [76].   
Skeletal muscle 
  
Skeletal muscle is one of the metabolically more active compartments of the 
body. Skeletal muscle requires a huge amount of FA for -oxidation. 
Physiologically, myocytes synthesize and store a limited amount of TG. The 
quantitatively more relevant source of FA is the uptake of non-esterified FA 
and lipoprotein-associated TG from the circulation [77]. The mechanisms 
responsible for this process are similar to those described for adipose tissue. 
Extracellular lipolysis is believed to be mediated mainly by LPL whereas the 
released FA are taken up via facilitated transport (CD36 and FATP1) [78].   
The first important step in FA oxidation is the formation of FA–CoA, mediated 
by ACC. When intracellular glucose concentration is low, such as in fasted 
conditions, ex novo lipogenesis is inhibited [77]. This leads to reduced levels 
of Malonyl-CoA, the main regulator of FA translocation to the mitochondrion.  
Malonyl-CoA, in fact, constitutively inhibits the carnitine palmitoyltransferase I 
transporter (CPT-I). CPT-I promotes the transport of FA into the 
mitochondrion where they enter the β-oxidative pathway, resulting in acetyl-
CoA production. Energy produced in the β-oxidation of fatty acids and the 
oxidation of acetyl–CoA in the Krebs cycle is used to generate ATP via 
oxidative phosphorylation [77]. 
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2 Structure, function and physiology of the 
plasma lipase family members 
 
 
The pancreatic lipase gene family comprises a group of genes that are widely 
conserved across species [79]. To date, ten different members have been 
identified in humans: phosphatidylserine-specific phospholipase A1 (PLA1A), 
membrane-associated phosphatidic acid selective phospholipase A1a (LIPH), 
membrane-associated phosphatidic acid-selective phospholipase A1b (LIPI), 
endothelial lipase (LIPG), human lipoprotein lipase (LPL), hepatic lipase 
(LIPC), pancreatic lipase (PL), pancreatic lipase-related protein 1 (PLRP1), 
pancreatic lipase-related protein 2 (PLRP2) and pancreatic lipase-related 3 
(PLRP3) (Figure I-3) [79]. Five of these enzymes (PL, LPL, HL, EL and 
PLRP2) exhibit substrate specificity for TG and catalyze the hydrolysis of FA. 
These proteins are thus collectively named TG lipases [1, 79, 80]. The five 
members are characterized by very different functional roles, with PL and 
PLRP2 being produced in the pancreas and secreted in the gastrointestinal 
tract and LPL, HL and EL being secreted in the vascular lumen. This latter 
subpopulation of lipases displays a high affinity for circulating lipoproteins. 
Their activity thus plays an essential role in both lipoprotein and tissue 
metabolism. Hydrolysis of phospholipid and TG in fact, not only remodels the 
circulating lipoprotein particles, thus modulating their properties and affecting 
their catabolism, but also generates free FA. Released FA can then reach the 
intracellular compartment and act as energy supply or signaling molecules. 
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Figure I-3: Phylogenetic relationships of members of the pancreatic lipase 
gene family.  
Phosphatidylserine-specific phospholipase A1 (PLA1A), membrane-
associated phosphatidic acidselective phospholipase A1a (LIPH), membrane-
associated phosphatidic acid-selective phospholipase A1b (LIPI), endothelial 
lipase (LIPG), human lipoprotein lipase (LPL), hepatic lipase (LIPC), 
pancreatic lipase (PL), pancreatic lipase-related protein 1 (PLRP1), pancreatic 
lipase-related protein 2 (PLRP2), pancreatic lipase-related 3 (PLRP3). LIPG, 
LPL and LIPC display a high degree of homology, possibly suggesting an 
origin from the same precursor. 
 
2.1 Structure  
 
Lipoprotein Lipase 
 
The LPL gene is located on chromosome 8p21.3 and encodes for a protein of 
448 amino acids. The gene includes 10 exons spanning ~30 kb [81]. The first 
exon encodes the 5'-untranslated sequence (containing most of the regulatory 
elements), the coding signal peptide sequence and the first two amino acids 
of the mature protein [81]. Exons 2-9 contain the remaining 1339 nucleotides 
that encode for the other 446 amino acids and include the translation stop 
codon. The 10th exon encodes for the long 3'-untranslated region of LPL 
mRNA (1948 nucleotides) (Figure I-4 A, table I-3) [82]. 
The amino acid sequence is extremely conserved among species [1]. 
Although the crystal structure of LPL has not been resolved yet, the high 
similarity to other lipases such as PL permits one to perform comparative 
modeling analyses [83]. The structure of LPL can be schematically divided 
into two big domains: amino terminal and C terminal. The amino terminal 
PLA1A
LIPH
LIPI
LIPG
LPL
LIPC
PLRP1
PL
PLRP2
PLRP3
5% Divergence
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domain contains the catalytic syte (Ser132, Asp156, His241) responsible for the 
lipolytic activity, and the lid domain that protects the enzymatic active site 
(Figure I-4B) [82]. The N-terminal domain of LPL also contains eleven amino 
acid residues (residues 65–68 and 73–79) that act cooperatively to bind 
apoC-II, the main activator of LPL. This same region has been proposed as 
the key interaction site between LPL and its inhibitors apoC-I and apoC-III) 
[82, 84]. The binding mechanism has not been elucidated but it seems to 
involve a destabilization of LPL interaction with lipid substrates. The C domain 
consists of a shorter amino acidic sequence and contains the Heparin-binding 
domain. This domain is believed to play an essential role in determining the 
substrate specificity across plasma lipases [84]. In native conditions, LPL 
spontaneously dimerizes to form head-to-tail LPL homodimers. This 
association is stabilized by the presence of disulfide bonds. Several studies 
demonstrated the importance of the dimer conformation in determining the 
activation status of LPL [85, 86]. The dimer in fact exist in two limit 
conformations: open, where the substrate has full access to the catalytic site, 
and closed, where the lid blocks any access to the catalytic pocket [83, 85, 
86]. 
Hepatic Lipase 
 
Hepatic Lipase is encoded by the LIPC gene, located on the chromosome 15 
(15 q 21.3) [87]. LIPC includes eight introns and nine exons, spanning ~69 
Kb. The gene map reveals a structure that is very similar to that of LPL and it 
is characterized by exons of comparable length (~200 bp) (Figure I-4A, table 
I-3) [21]. The 5’ non translated region contains the binding site for positive 
transcription factors, such as HNF4 1 and 2, Coup (chicken ovalbumin 
upstream promoter) and PPAR 1 and 2 [21]. 
The HL protein is composed by 499 amino acids. After synthesis HL pro-
protein loses the 22 amino acids leader peptide [88]. The resulting mature 
protein consists of 477 amino acids [88]. Similar to LPL, the enzyme can be 
divided in to two major regions: the short carboxy-terminal domain and the 
wide amino-terminal domain. The C domain contains the highly conserved 
PLAT (Polycystin-1, Lipoxygenase, Alpha-Toxin) domain. The amino terminal 
 32 
domain contains the catalytic triad (Ser146, Asp 172, and His257) and the lid 
domain, covering the active site [83]. At the center of the protein there are ten 
cysteine residues that are likely involved in the formation of dysulphide bonds. 
Finally, HL contains four heparin-binding sites, responsible for the protein 
binding to heparan-sulphate residues at the cell surface [21].  
Endothelial Lipase 
 
The  LIPG gene, coding for Endothelial Lipase is located on chromosome 18 
(18q21.1) (Figure I-4 A, table I-3). It is composed of 10 exons and 9 introns, 
spanning ~10.4 Kb. LIPG was first cloned in 1999 by two different research 
groups [89, 90]. Hirata and colleagues isolated LIPG in human umbilical 
endothelial cells (HUVEC), through a subtraction hybridization methodology 
that was aimed at characterizing genes preferentially expressed in 
differentiating cells [90]. This approach led to the identification of a ~500 
amino acids fragment that displayed a high degree of structural similarity to 
LPL (44%) and HL (41%)[90, 91].  
Jaye and colleagues, the same year, identified EL following a completely 
different approach [89]. This group was in fact screening genes that were 
differentially upregulated in macrophage-like cells (THP-1) upon stimulation 
with oxidized LDL. Nucleotide sequencing of the amplified genes that were 
specifically expressed in THP-1 exposed to oxidized LDL, demonstrated the 
presence of a clone with a unique open reading frame of 1500 nucleotides. 
The analysis of the deduced primary structure revealed features that were 
consistent with the two already known plasma lipases [89]. The N-terminal 
region includes an 18-amino acid signal peptide that mediates the enzyme 
secretion. Analogously to what reported for HL and LPL, the primary structure 
of endothelial lipase exhibit ten cysteine residues that are likely responsible 
for the formation of disulfide bonds. This feature is highly conserved among 
lipases and determines the tertiary structure of the protein [83]. The catalytic 
triad (Ser151, Asp175 and His 256) is located in the N-terminal domain and 
Ser 151 is included in the characteristic ‘GXSXG’ lipase motif. The active site 
is protected by the presence of lid domain consisting of 19 amino acids [83]. 
This region likely contributes to the specificity for triglyceride and 
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phospholipids. Notably, homology models of HL, LPL, and EL demonstrated 
that the binding pockets of the three lipases display very different properties. 
EL binding pocket seems to be more flexible and its conformation changes 
during the catalysis process [83]. Based on different modeling strategies four 
possible heparin binding sites (14- KLHKPK-19, 282-RFDKK-285, 292-RKNR-
295, 304-KKMRNKR-310 and 427-RRIRVK-432) and five glycosylation sites 
have been proposed.  The comparison of EL sequence with that of PL 
suggests that the PLAT domain, a region that is shared among all the 
Triglyceride lipases, is probably located in the region 347-482 (Prosite Prorule 
annotation)[92, 93]. The predicted molecular weight of mature EL is 56794 Da 
[94]. When assessed by western blot, human EL exists in at least two different 
forms, characterized by an apparent molecular weight of 40 and 68 KDa [94, 
95]. The 68 KDa variant probably represents the fully glycosylated protein, 
whereas the 40KDa is probably an alternative splicing or post translational 
cleavage product. Human LIPG is a heparin binding protein, behaves as a 
homodimer with a proposed head-to-tail conformation [94] and is subject to 
proprotein convertase cleavage at a site in the ‘hinge’ region separating the 
N- and C-terminal enzyme domains [96]. 
 
Gene Chromosome Exons 
Transcript 
length 
Translation 
length 
Panel 
LPL 
Chr8 
(19,901,717-19,967,258) 
10 3846 475 
Figure 
I-4A 
LIPC 
Chr15 
(58,410,569-58,569,843) 
9 2751 499 
Figure 
I-4B 
LIPG 
Chr18 
(49,560,699-49,599,182) 
10 10441 500 
Figure 
I-4C 
 
Table I-3 Summary of LPL, LIPC and LIPG gene characteristics  
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Figure I-4. LPL, HL and EL gene and protein structure.  
 
Panel A-B-C: LPL, HL and EL gene structure. The schematic illustrates exons 
(full boxes), intronic regions (thin line) and untranslated regions (empty boxes) 
(Ensembl genome browser [97]). Panel D: Sequence alignment of LPL, HL 
and EL amino acid sequence. Amino acid similarity decreases from red 
(identical)>pink>yellow>white. The amino acids of the catalytic triad are 
indicated with stars. The amino acids included in the lid region are marked 
with a black box. 
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2.2 Post-transcriptional modifications 
 
 
 LPL, HL, and EL are all associated with the luminal side of capillaries where 
they are anchored to proteoglycans exposed on the endothelial cell 
membrane. After synthesis lipases undergo several post-transcriptional steps 
that end up with the translocation of the mature dimeric enzymes in the 
vascular lumen. The dimerization and glycosylation are early events in lipases 
maturation and happen in the ER. This step is crucial and seems to require a 
transmembrane protein named lipase maturation factor 1 (LMF1). LOF 
mutations in this gene have been associated with combined lipase deficiency 
(cld) [98]. Homozygous cld mice develop severe hypertriglyceridemia and die 
after birth [99]. A comparable lipid phenotype has been reported in humans 
carrying loss-of-function mutations Y439X and W464X in the human 
orthologue gene. Lack of  LMF1 leads to lipases misfolding and aggregation-
accumulation of immature precursors in the ER [98, 100]. Although the exact 
mechanism of action of LMF1 has not been elucidated, its activity seems to 
be specific for a subclass of lipases including LPL, HL, and EL but not the 
highly homologue PL [98, 101]. 
After glycosylation and folding into mature form, a fraction of the mature 
lipases is translocated to the Golgi apparatus for further processing whereas a 
large pool is retained in the ER as inactive precursor. Lipases are finally 
secreted into cytoplasm via secretory vesicles. Part of the vesicles are then 
sorted to the lysosomes for degradation and part are delivered to the 
intracellular side of the plasma membrane where they interact with heparan 
sulphate proteoglycans (secretatogue) and are delivered to the vascular 
lumen. 
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2.3 Tissue expression 
 
Lipoprotein Lipase 
 
Lipoprotein lipase is synthesized in several parenchymal cells. After 
synthesis, it is secreted in the extracellular compartment and transported to 
the surface of endothelial cells. Here it anchors to the cell membrane through 
binding to heparan sulphate proteoglycans [74]. The exact mechanism 
underlying this process has not been fully clarified. LPL mRNA has been 
isolated in different tissues. It is very abundant in heart, skeletal muscle and 
adipose tissue, where it is believed to exert trophic functions [31, 102, 103]. 
Its role in other tissues is less clear. In the kidney, LPL mRNA is found in 
tubular and glomerular parenchymal cells whereas the protein seems to be 
localized at the endothelial level [104, 105]. In the mammary gland LPL is 
highly expressed only during lactation [106]. It seems to be synthesized by 
adipocytes and secreted in the milk in association with lipid droplets [107]. 
Finally, in some adult tissues LPL is expressed in infiltrating phagocytic cells 
(macrophages in lung and spleen, Kupffer cells in the liver). The role of LPL in 
the liver is still controversial. In the early phases of embryo development and 
in the first 3 weeks after birth LPL expression is high and it progressively 
decreases with development [108]. In the adult liver it is normally detectable in 
endothelial cells lining the hepatic sinusoid but not hepatocytes [109]. 
However, in certain conditions LPL expression can be rescued [110]. 
Inflammation and fibrates decrease LPL expression in macrophages but 
increase the expression in the liver [69, 111, 112]. When LPL is selectively 
overexpressed in the liver LPL-/- mice develop hypertriglyceridemia, insulin 
resistance and steatosis [108, 113].  
  
Hepatic Lipase 
 
Hepatic lipase is synthesized and secreted mainly in the liver and binds to 
heparan sulfate proteoglycans (HSPG) on the cell surface of hepatocytes and 
endothelial cells [114, 115]. It has also been isolated in steroidogenic tissues 
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such as adrenals and ovaries and macrophages infiltrating the atherosclerotic 
plaque [116-119]. 
Endothelial Lipase 
 
The EL expression pattern is unique compared to other plasma lipases. 
Endothelial lipase is expressed in endothelial cells both in in vivo and in vitro. 
Immunohistochemistry studies have revealed that the expression of EL varies 
in different vessels. Intense staining has been reported in large vessels such 
as aorta and major arteries in the kidneys, spleen and lung [120]. EL seems to 
be abundant in the microvessels in the spleen and lung whereas it seems to 
be poorly expressed in other capillary bed [90]. EL mRNA and protein have 
been detected in several other tissues. In vivo data indicate that EL may play 
an important role in reproduction. EL mRNA has been detected in mouse 
embryos (E8.5 to E11.5), but not later in development [121]. In adult mice, EL 
mRNA expression is high in ovaries during pregnancy and testes [121]. In-situ 
hybridization studies have demonstrated that placenta is one of the sites with 
highest expression of EL [89, 90]. Both LPL and EL protein have been 
detected in the placental villus where they are likely involved in the hydrolysis 
of TG and PL-derived FA that can be thus delivered to the fetus. EL is mainly 
synthesized in endothelial cells and then transported to the 
syncytiotrophoblasts cell surface [122, 123]. EL mRNA has been detected in 
lungs, where it has been suggested to play a role in the metabolism of the 
surfactant fluid [90]. Finally, EL is abundant in thyroid glands in the epithelial 
cells that line the follicles [124]. Its functional significance in the thyroid is not 
known. It has been demonstrated that HL is regulated by the thyroid hormone 
and its activity it’s reduced in severe hypothyroidism leading to increased 
levels of HDL cholesterol [125]. It is thus possible that EL levels may be 
similarly regulated by the same hormonal axes.  
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2.4 Activity, physiology and regulation of plasma 
lipases 
 
Lipoprotein Lipase 
 
Lipolytic activity 
 
LPL affects plasma levels of all the lipoprotein subclasses. Its preferential 
substrates are chylomicrons and VLDL, where it is able to hydrolyze TG and 
to a lesser extent PL (Figure I-5 B).  Although its role in TG-rich lipoprotein 
metabolism had been first identified in 1943, many aspects of LPL reaction 
and regulation have not been clarified [126].  
The interaction between lipoproteins and LPL happens in the vascular 
compartment. Several factors such as the diameter of the vessel, the blood 
flow rate, LPL density at the vascular wall, and the diameter of the lipoprotein 
itself can affect this initial step. The sequestration of large particles such as 
chylomicrons in small vessels facilitates LPL-lipoprotein interaction and 
maximizes the lipolysis rate [2]. This scenario typically occurs in the 
postprandial phase. The LPL-lipoprotein interaction seems to follow a 
competitive kinetic. Different lipoprotein subclasses such as VLDL and 
chylomicrons can compete for the binding to LPL. The relative concentration 
of lipoprotein subclasses can thus influence the lipolytic rate and plasma FFA 
concentration. 
LPL substrate specificity is higher for TG than to PL. Among TG, LPL is able 
to hydrolyze any FA but it displays a higher specificity for unsaturated FA 
such as oleate. Furthermore, FA in the 1 position of glycerol and 
Phosphatidylcholine backbone (sn-1) are hydrolyzed more efficiently than 
those in the 2 position [2]. 
Once the substrate reaches the catalytic site it is hydrolyzed into FA and ester 
derivative (Figure I- 5B). The overall mechanism of reaction is shared among 
all the plasma lipases and it’s typical of the α/β hydrolase family.  The active 
site of EL, LPL, and HL consists of a highly conserved catalytic triad. The 
substrate hydrolysis starts with the nucleophilic addition of the hydroxyl group 
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of the catalytic serine residue to the carbonyl carbon atom of the glycerol-FA 
ester bond (Figure I- 5A). This generates a tetrahedral intermediate that is 
stabilized by two hydrogen bonds between the negatively charged carbonyl 
oxygen atom and the amino groups of two amino-acid residues of the active 
site. The further transfer of a proton to the oxygen atom induces the cleavage 
of the ester bond, the release of the alcohol product, and the formation of the 
serine-ester. The last step is the deacylation, in which a water molecule 
hydrolyzes the covalent bond between serine and acyl derivatives [127, 128]. 
 
Figure I- 5. The lipase-mediated TG hydrolysis reaction.  
 
Panel A Mechanism of the lipase reaction. (1) Nucleophilic addition of the 
serine OH to the ester bond; (2) tetrahedral intermediate; (3) acyl-enzyme and 
released alcohol (4) regenerated enzyme and released acyl product). Panel B 
LPL- induced hydrolysis of triglycerides  
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Non-lipolytic activity 
 
LPL can mediate receptor-independent uptake of the apoB-containing 
lipoproteins [129-131]. This is partially explained by the fact that LPL-derived 
VLDL remnants and IDL have higher affinity for LDL-R located on peripheral 
cells such as macrophages.  Furthermore, LPL activity increases the binding 
affinity of apoE-containing lipoproteins, for three LRP, LRP-2, and VLDLR 
[132-134]. 
Regulation of lipoprotein lipase activation and expression 
 
Full activation of lipoprotein lipase requires the presence of a specific 
cofactor, apolipoprotein C-II. This is a unique feature of LPL, since no 
activator seems to be required for HL and EL activity. The binding site for this 
apolipoprotein has been identified in the amino terminal region of LPL. It has 
been suggested that apoC-II promotes LPL activity by facilitating the 
interaction of LPL with the substrate. apoC-II is present in both HDL and TG-
rich lipoproteins. Genetic defects that lead to decreased apoC-II levels are 
associated with hypertriglyceridemia [135-137]. Interestingly overexpression 
of apoC-II leads to a similar phenotype. A possible explanation is that the 
increased content of surficial lipoproteins can negatively affect the initial 
interaction between lipoprotein and cell surface lipases [138].  
The ability of LPL to bind both proteoglycans and lipoproteins is in fact 
essential for a fully efficient activity. Virtually any factor that decreases this 
bridging interaction can negatively impact the lipolysis rate.  
A recently identified protein that promotes LPL-mediated TG-rich lipoprotein 
lipolysis is GPIHBP1 (Glycosylphosphatidylinositol Anchored High Density 
Lipoprotein Binding Protein 1) [139]. This is a glycosylphosphatidylinositol-
anchored protein that plays a major role in transporting lipoprotein lipase 
(LPL) from the subendothelial spaces to the capillary lumen. Once in the 
vascular lumen GPIHBP1 is able to bind positively charged apolipoproteins 
and LPL. It has been proposed that this molecule may stabilize LPL binding to 
the endothelial cell membrane and promote its interaction with chylomicrons. 
The exact mechanism is still unknown but missense mutations in GPIHBP1 
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gene have been associated with hyperchylomicronemia [140-142] 
ApoC-III is a small apolipoprotein that circulates on both TG-rich lipoproteins 
and HDL. Apo C-III affects the TG-rich lipoprotein metabolism at different 
levels [143]. One of the proposed mechanisms involves the negative 
regulation of LPL activity [144]. In vivo studies in apoc3 transgenic and KO 
mice corroborated this hypothesis and showed that apoC-III delays TG 
hydrolysis [145-147]. The molecular mechanisms underlying apoC-III-
mediated inhibition are still under investigation. One proposed mechanism is 
that apoC-III displaces LPL from lipid emulsion particles and expose LPL to 
additional inactivating factors such as ANGPTL3 and 4 [148]. 
apoA-V has emerged as a potent modulator of plasma TG [149, 150]. 
Contrary to apoC-III, it is thought to exert its effect through different 
mechanisms [143]. The effect on LPL activity seems to be secondary to an 
apoA-V mediated increase in VLDL and Chylomicrons availability at the 
endothelial wall. apoA-V is in fact able to promote the binding of TG-rich 
lipoproteins to proteoglycans. This stabilization of the substrate maximizes the 
LPL-lipoprotein interaction and results in increased lipolysis. In vivo studies in 
Apoa5 KO and transgenic mice have demonstrated that apoA-V plasma levels 
are inversely correlated with triglyceridemia [151, 152].  
ANGPTL3 and 4 genes are expressed predominantly in the liver, and encode 
for secreted proteins that belong to the family of angiopoietins. Their structure 
comprises an N-terminal coiled-coil domain and a C-terminal fibrinogen-like 
domain [153, 154]. ANGPTL3 and 4 play and important role in glucose and 
lipid metabolism [155, 156]. Loss of function mutations in ANGPTL3 are 
associated with betahypolipoproteinemia [157]. In vivo studies in KO and 
transgenic mice have demonstrated that Angptl3 and 4 levels are inversely 
correlated with LPL activity and positively correlated with TG plasma levels 
[154, 158, 159]. In addition to their effect on LPL, Angptl3 and 4 are also able 
to inhibit HL and EL. The mechanism by which Angptl3 and 4 inhibit LPL 
appears to be different. ANGPTL3 inhibition can be overcome by heparin and 
translates into a net decrease in LPL catalytic activity [160]. It has been 
hypothesized that this effect may be mediated by the recruitment of proprotein 
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convertases PCSK6 and FURIN cleavage and dissociation of LPL from the 
cell surface [154, 160, 161]. ANGPTL4 Is believed to inhibit LPL by promoting 
the monomerization and unfolding of LPL.  
LPL is expressed in several tissues and its synthesis is regulated by different 
nutritional and hormonal pathways. Fasting and refeeding regulates LPL 
expression in a tissue-specific manner [73, 162]. In the postprandial state, 
LPL synthesis is high in adipocytes and low in heart and skeletal muscle [73, 
163]. In the adipose tissue this effect seems to be mediated by insulin and by 
glucose level itself through distinct pathways [162]. Short-term high 
carbohydrate diet is in fact sufficient to increase LPL without affecting insulin 
sensitivity [163]. Insulin on the other hand has a direct positive effect on LPL 
transcription and glycosylation [164-166]. Glycosylated LPL is more efficiently 
secreted into the vascular compartment and seems to be more catalytically 
active. During fasting, on contrary, LPL levels in the adipose tissue fall 
drastically [167]. This latter effect seems to be mediated by an increased 
fraction of LPL that is converted to the inactive form rather than by decreased 
LPL synthesis [164-167].  
LPL expression in the heart responds to fasting and refeeding through a post-
transcriptional regulatory mechanism. During fasting, heparin-hydrolysable 
LPL that represents the active enzyme pool, is increased [168, 169]. 
Finally, LPL expression can be modulated by other hormonal axes. It has 
been observed that catecholamines reduce adipose tissue LPL, thyroid 
hormones increases LPL activity in rodents and growth and sex hormones 
inhibit LPL in adipose tissue while increasing its activity in skeletal muscle and 
heart [170]. 
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Hepatic Lipase 
 
Lipolytic activity 
 
Hepatic lipase is mainly synthesized by hepatocytes and hydrolyzes TG and 
PL in chylomicron remnants, IDL and HDL [33, 171]. HL active site is 
characterized by the presence of the α/β catalytic triad and the hydrolysis 
reaction is thought to follow the same general mechanism (Figure I- 5A). 
Despite the evident high degree of homology with LPL, HL displays a different 
substrate specificity and the biochemistry of HL reaction is differently 
regulated  [172]. The first striking difference is that HL does not require apoC-
II as activator and its reaction cannot be inhibited by NaCl [173]. This 
biochemical peculiarity is the basis of most of the currently used activity 
assays. HL post heparin plasma activity indeed is defined by subtracting 
NaCl-sensitive LPL activity from total post heparin lipase activity [174, 175]. 
Structure-function studies on HL/LPL chimeric proteins suggested that the 
different catalytic properties may be due to differences in the amino-terminus 
domain [84, 176]. The substrate specificity and the different heparin-binding 
properties may instead be explained by the sequence differences in the C-
terminal domain [93]. In this regard, the lid region seems to be responsible for 
the different PL/TG lipase activity ratio. In fact, the lid region changes its 
conformation when it binds a substrate and the flexibility of the lid can 
determine which substrates ultimately reach the active site [93, 177]. Notably 
the degree of a sequence homology between the lids of HL, LPL and EL is 
low. The LPL lid permits a high specificity for TG with very low PL activity [93, 
177]. HL, on the contrary, is less specific. The absolute (in bulk) substrate 
specificity is comparable for TG and PL [178]. When the substrates are diluted 
in the surface of micelles HL seems to prefer TG rather than PL 
(TG>DAG>PE>PA>PC) [177, 178].  
Furthermore, HL seems to be less stereo-selective than LPL and shows a 
comparable affinity for FA in sn1 and sn3 on the glycerol backbone [178].  
The relevance of these observations in vivo is not clear. The relative 
magnitude of TG and PL lipase activity may be determined by the substrate 
availability rather than by the different specificity.  
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The impact of HL activity on plasma lipoprotein metabolism is complex and 
reflects the different effects on single lipoprotein subclasses. TG-rich 
lipoproteins are firstly hydrolyzed by LPL, that is quantitatively more abundant 
in peripheral tissues. HL on the other hand converts VLDL and CM remnants 
into LDL by promoting the hydrolysis of TG and PL [179, 180]. The result is 
the formation of small, dense LDL particle. In a similar fashion HL converts 
large, TG-rich HDL2 into small HDL3 [181, 182]. Consistently, subjects with 
HL deficiency display elevated plasma concentrations of intermediate density 
lipoproteins and HDL  [179, 180].  
The very first event in HL reaction is the interaction between HL and 
lipoproteins. This step is not clear and different models have been proposed. 
In the early models, HL was described by analogy with LPL. After heparin 
injection LPL is massively released in the circulation [183]. Although LPL 
activity in the post heparin plasma is extremely high, the enzyme is less stable 
and is more prone to cleavage into inactive monomers [148]. This observation 
corroborated the importance of proteoglycans in stabilizing LPL and mediating 
the interaction with lipoproteins. To what extent bound and unbound forms 
contribute to the overall plasma lipolytic activity in physiological conditions is 
not known. Recent studies suggest that HL may be inactive when it is bound 
to the cell surface and only after it is released in the circulation it is converted 
to the active form [171]. According to this model, the liver may function as a 
reservoir of inactive EL that can be initially taken up by HDL and then 
released into the circulation in the active form [171, 184]. HL activation may 
thus require a two-step process involving an HDL-mediated displacement 
from endothelial cell proteoglycans and a second displacement from HDL 
particles [184, 185]. Some studies suggest that HDL protein and lipid 
composition may in fact modulate this process. The presence of apoE on HDL 
particles appears to reduce the initial binding of HDL to HL and translates into 
a reduced HL activity [185]. During the postprandial phase, apoE is 
exchanged with TG-rich lipoproteins and this results in a lower HDL-apoE 
content. Interestingly in this condition HDL's ability to activate HL is higher.  
ApoA-II particle content seems to be one of the main negative regulators of 
HL activation rate. ApoA-II in fact enhances HL affinity to HDL. This increases 
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the displacement of inactive HL from endothelial cells but decreases the 
release of HDL-bound HL into the circulation [186, 187].  
 
Non-lipolytic activity 
 
In addition to the lipolytic activity, HL plays a role in the uptake of HDL and 
apoB-containing lipoprotein remnants by cell receptors. For instance, it has 
been demonstrated that hepatocyte uptake of plasma lipoproteins is 
increased by HL. The mechanism does not require catalytically active HL and 
seems to involve the binding of HL to LRP, LDLr and proteoglycans [75, 188, 
189].  Overexpression of catalytically active human HL in HL KO mice 
overexpressing apoB-48 or apoB-100 was sufficient to induce a significant 
reduction in apoB-containing lipoprotein plasma levels [190].  
Regulation of hepatic lipase activation and expression 
 
The HL activation status seems to be highly dependent on the ratio between 
proteoglycan-bound (inactive) and released (active) form. The equilibrium 
between these two pools of HL is probably influenced by the lipoprotein 
composition. ApoE and apoA-II are the two main inhibitors of HL activity and 
their mechanism of action seems to be related to their ability to stabilize HL in 
its proteoglycan or HDL-bound form [185]. 
Several hypothetic regulatory elements have been described in the murine 
Lipc promoter [21, 191]. In vivo and in vitro studies showed a strong 
association between sterol intracellular levels and HL expression. In HepG2 
cells, the pharmacological inhibition of the cholesterol biosynthetic pathway 
increases the expression of HL mRNA and protein [192]. In studies in rats, 
high cholesterol diet downregulates HL protein expression [193, 194]. Finally, 
in humans, the treatment with bile acid resins increase HL plasma levels 
[195].  
HL activity in post heparin plasma is affected by sex hormones. Estrogens 
decrease HL activity whereas progestinic and androgenic hormones increase 
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HL activity [196, 197]. These observations have been widely supported by 
human studies either in physiological conditions (pregnancy, postmenopausal 
status) or upon pharmacological supplementation [197-200]. At a 
physiological level, HL expression seems to be gender dependent. Women in 
fact seem to have larger, less dense LDL and lower hepatic lipase activity 
[201-203] . Men, on contrary, display higher HL activity that is accompanied 
by the formation of denser and smaller LDL [204].  
Whether HL is responsive to insulin is still controversial. Insulin stimulation of 
HL transcription is required during embryogenesis [191]. In adult humans the 
association is not clear. There is a positive association between insulin levels 
and HL activity in control subjects ad insulin-responsive diabetic patients [205] 
whereas type-I diabetic subjects display a significantly reduced HL activity 
[206, 207].  
Catecholamines, finally have been associated with a reduced secretion of HL. 
This downregulation of HL protein seems to happen both at a transcriptional 
and post-transcriptional level [208-210].  
Endothelial Lipase 
 
Lipolytic activity 
 
Endothelial lipase displays the highest PL activity among the plasma lipases. 
Although in an initial study no TG lipase activity was reported, further 
investigations demonstrated that EL is capable of hydrolyzing triacylglycerol 
[89, 90].  Unlike LPL, EL does not require apoC-II or other activators [90, 211]. 
Biochemical studies on EL lipolysis demonstrated that this enzyme is inhibited 
by the addition of serum and, similar to LPL but not HL, it is sensitive to NaCl 
[211]. Its activation/inhibition profile is thus intermediate between LPL and HL. 
The specific factor responsible for dose-dependent serum inhibition is not 
known but its effect extends to both the TG and PL activity.  
McCoy and colleagues tested the relative affinity of LPL, HL, and EL for TG 
and PL in vitro [211]. In these analyses they used a lipid emulsion containing 
TG and PL. This substrate allows one to determine the activity independently 
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of potential lipoprotein-dependent factors such as the protein composition. 
The results of this study indicated that the TG:PL activity ratio was 140 for 
LPL, 24 for HL and 0.65 for EL. In a second set of experiments the ability of 
lipases to hydrolyze isolated lipoproteins was tested.  The authors showed 
that when incubated with HDL, EL displayed the highest catalytic activity 
(measured as total released FA). LPL on contrary displayed the highest 
affinity for TG-rich lipoproteins and HL seemed to have an intermediate 
phenotype (fig 6). EL has been shown to have a positional specificity for fatty 
acids in position 1 (sn-1) of Phosphatidylcholine [212, 213] Furthermore, the 
phospholipid FA composition seems to affect EL affinity to the substrate. 
Incubation of EL with synthetic reconstituted HDL showed that the presence 
of a long chain FA in position 2 increased the EL activity [214]. Finally, among 
the natural PL, EL preferentially hydrolyzes phosphatidylethanolamine 
(relative specificity: phosphatidylethanolamine > Phosphatidylcholine > 
phosphatidylserine > Phosphatidic Acid) [215]. The molecular explanation for 
this peculiar substrate specificity is probably the lid region sequence. This 
region is the less conserved among the plasma lipases [89, 90]. In a recent 
study the structure of EL, LPL, and HL has been modeled by analogy with 
pancreatic lipase. The comparative study of their structure and the 
computational analysis of their predicted binding to known inhibitors revealed 
that EL lid region is more flexible and the conformation of EL active site 
changes more during the catalytic process [83].  
The physiological role of EL in lipoprotein metabolism has not been fully 
elucidated. Since it was firstly cloned in 1999, EL has been identified as a 
major regulator of HDL-C in vivo [89]. Although its activity against HDL is 
extremely high recent studies have highlighted a substantial hydrolytic activity 
towards apoB-containing particles. Early studies showed that, in mice, 
overexpression of human EL in the liver induces a dramatic decrease in 
circulating HDL and apoA-I levels [89, 213]. The effect on apoB-containing 
lipoproteins was more modest and overexpression of hEL in LDLr KO mice 
lead to a 50% reduction of non-HDL cholesterol [89].  
In a more recent study instead, overexpression of EL in strains with high 
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levels of apoB-containing lipoproteins lead to significant decrease in VLDL, 
LDL, PL, TG, total cholesterol and apoB levels [216]. This dramatic change 
was due to an impaired apoB-containing particles catabolism. Overexpression 
of a catalytically inactive EL (ELS149A) was not only ineffective but also 
impaired the endogenous EL activity [216]. Taken altogether these data 
indicate that EL enzymatic activity may contribute to apo-B containing 
lipoprotein metabolism. 
Studies on EL-deficient animals proved the role of EL in HDL metabolism. Jin 
and colleagues took advantage of antibody-mediated inhibition of murine EL 
(mEL). In female wildtype mice, EL deficiency caused a significant increase in 
both HDL-cholesterol and PL (+29.5 and 27% at 24 hrs, respectively) [217]. 
The same experiment was performed in human apoA-I transgenic mice and 
HL-deficient mice. In apoA-I transgenic mice, 24 hours after injection of anti-
mEL antibody plasma levels of total cholesterol, HDL-C, and phospholipid 
were significantly increased (+15, 20 and 23% respectively) [217]. The 
authors demonstrated that these changes were due a slower HDL-
phospholipid catabolic rate that translated into a net increase in the number of 
HDL particles. The study of HL deficient mice provided interesting results. 
Similar to what observed in the other two strains, EL inhibition raised HDL-C, 
total cholesterol and PL. In addition to that, HL–/– mice had larger HDL and 
they displayed an increase in triglyceride levels [217]. This suggests that EL 
and other lipases may have concerted activity on plasma lipoprotein 
remodeling and the effects of EL on triglyceride-rich lipoprotein metabolism 
may also be magnified in the absence of HL. 
EL KO mice have been developed by two different groups. The 
characterization of these models showed very contradictory results. In both 
models, a gene dose-dependent increase in HDL-C was observed but the 
analysis of HDL composition showed no difference in the HDL particle number 
and composition or an increase in HDL particle size [213, 218]. However, very 
different effects were observed on apoB-containing lipoprotein levels. Ma and 
colleagues didn’t observe any change in both LDL and VLDL plasma levels 
either on chow or high fat diet [219, 220]. On the contrary Ishida and 
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colleagues observed a dramatic increase in LDL-C levels (+90%)[213].  
Non-lipolytic activity 
 
In vitro and in vivo data demonstrated that, in addition to its enzymatic activity, 
EL modulates lipoprotein metabolism by promoting lipoprotein uptake.  
Strauss and colleagues firstly observed this effect in HepG2 cells. In the 
study, cells were infected with adenovirus encoding EL, LPL or LacZ. Cells 
were then incubated with dual-labeled HDL (3H-Cholesterol esters and I-125 
total protein) and binding, holoparticle uptake and CE-selective uptake were 
measured [221]. Results indicated that both HDL particle and HDL-CE uptake 
were significantly increased in EL and LPL expressing cells whereas HDL 
binding was significantly increased in EL-overexpressing cells only. In order to 
test whether this effect was secondary to EL lipase activity, the same 
experiment was repeated in presence of the EL inhibitor tetrahydrolipstatin 
(THL) or using a mutant catalytically-inactive EL. Paradoxically the presence 
of inactive or inhibited EL lead to a further increase of all the measured 
parameters. When the authors analyzed the density of EL protein at the cell 
membrane, they observed that in absence of any catalytic activity the amount 
of EL was higher. They concluded that fatty acids that are liberated from 
phospholipids release EDL from the cell surface and thus impair its non-
catalytic activity [221].  
In similar experiments Fuki and colleagues confirmed the ability of EL to 
bridge lipoproteins to the cell surface [222]. Consistent with the results from 
Strauss, no difference was noticed in cell uptake between cells expressing 
WT EL or the EL-S149A catalytically-inactive mutant. Furthermore, in this 
study the authors demonstrated that EL binding to heparan sulfate 
proteoglycan (HSPG) is required to this activity and that the bridging capacity 
is not HDL-selective. Interestingly cells expressing EL, LPL, and HL all 
displayed a high bridging capacity towards VLDL and LDL compared to 
control cells whereas the activity towards HDL was moderate but significantly 
higher for EL and HL compared to LPL. The absolute bridging capacity (total 
I-125 protein counts), represents the sum of different processes namely 
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binding, uptake and degradation. The authors showed that incubation with 
either LDL or HDL in fact leads to a substantial increase in lipoprotein binding 
to the cell surface but notably, after binding, almost all LDL particles were 
internalized and degraded, whereas HDL was mainly released in the medium. 
The observed effect is probably a result of  two distinct binding kinetics. Fuki 
and colleagues speculate that VLDL and LDL interact with EL through two 
different binding sites. The lipid component binds to EL with low affinity and 
high capacity whereas apoB binds to EL with high affinity. Surprisingly the 
HDL binding kinetics seems to be described by a low affinity high capacity 
interaction and this process is significantly magnified by increasing HDL-
clustering. These findings support the idea that EL alone can promote the CE 
uptake from HDL particles. The relevance of this process to apo-B containing 
lipoprotein metabolism is less clear. Data from this study indicate that most of 
LDL and VLDL are internalized and degraded and authors conclude that EL 
alone is probably not sufficient to promote a significant CE uptake from these 
lipoproteins. Nevertheless in vivo EL coexist with LPL and HL in the 
endothelial wall and it is possible that its high capacity lipid binding may 
facilitate VLDL and LDL metabolism through a mechanism that involves the 
combined activity of multiple lipases.  
In an in vivo study, Broedl and colleagues tried to address this question by 
inducing the expression of catalytically inactive EL-S149A in WT, apoA-I 
transgenic, and HL-deficient mice. In contrast to what observed in vitro, 
catalytically inactive ELS149A didn’t induce any reduction of HDL-C or apoA-I 
plasma levels in wild-type and apoA-I transgenic mice, suggesting that PL-
hydrolysis may be a key step in HDL catabolism.  A moderate reduction of 
total and HDL-C was observed in HL-KO mice [223]. 
 
Regulation of endothelial lipase activation and expression 
 
EL was first isolated in endothelial cells and macrophage-like cells. Hirata and 
colleagues identified EL through an approached aimed to discriminate genes 
that were selectively expressed in activated endothelial cells [90]. Given this 
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premise, many efforts have been focused on investigating whether factors 
known to stimulate endothelial cell activation were able to modulate LIPG 
expression. In cultured HUVEC, several pro-inflammatory stimuli such as 
cytokines, shear stress and cyclic stress positively regulated EL mRNA [95]. 
HUVEC and HCAEC stimulated with IL-1  and TNF-  in fact displayed a 6.5 
and 4 fold increased EL mRNA [95]. An independent study confirmed that 
both EL mRNA and protein expression are upregulated upon stimulation with 
IL-1  and TNF-  in a dose-dependent fashion [224]. The protein is in the 
active form and the increased expression translates in increased 
phospholipase and TG lipase activity in the cell medium. The mechanism 
underlying the positive regulation of EL expression is not completely clear but 
it seems to involve NF-kB pathway [224-227]. In obese subjects, plasma 
inflammatory cytokine levels are directly correlated with plasma EL 
concentration. Furthermore, LPS-induced endotoxemia significantly increases 
plasma EL levels [228].   
In vitro studies showed that in brain capillary endothelial cells EL expression 
was reduced by treatment with LXR and PPAR agonists whereas in mice the 
same effect was observed after treatment with SREBP inhibitors [229, 230].  
Similar to LPL and HL, EL activity is also regulated at the post-transcriptional 
level. The intracellular maturation of EL is affected by LMF- 1 activity [98, 
100].  
After secretion, EL activity may be regulated through the modulation of its 
binding to heparan sulphate proteoglycans, though cleavage-inactivation 
(Proprotein Convertases such as PC5/6) or through the binding to lipase 
inhibitors (ANGPTL3 and ANGPTL4) [96, 231-234].  
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3 Lipases and metabolic disorders 
 
Lipases play a major role in both plasma lipoprotein metabolism and tissue FA 
utilization. Primary and secondary defects in lipase activity have been 
associated with several traits of metabolic disorders including dyslipidemia, 
atherosclerosis, obesity, and diabetes. Given the very different substrate 
specificity and role in lipoprotein and tissue metabolism, factors that 
selectively impair EL, HL, and LPL activity translate in different phenotypes. 
Lipoprotein Lipase  
 
The current knowledge about the role of LPL in the development of 
hypertriglyceridemia derives largely from the observation of the clinical 
phenotype of human carriers of genetic mutations.  
Complete LPL deficiency in mice is not compatible with life. LPL-/- mice 
survive during gestation but die within three days after birth. Necropsy reveals 
that pups have no TG storage in the tissues and display a massive 
hypertriglyceridemia (>20000 mg/dL) and hypoglycemia [235]. Heterozygous 
mice have hyperinsulinemia and tend to have fat mass increase with aging. 
[236]. This phenotype seems to be rescued when LPL is reconstituted in heart 
and liver [108, 237].  
The first report of a genetic case of lipase deficiency in humans was in 1932 
[238]. The patient was a young boy who displayed eruptive xanthomas, 
hepatosplenomegaly and milky plasma. All the symptoms were reverted with 
fat free diet and the phenotype was not secondary to any other known 
pathology. Since his parents were first cousins, the disease was classified as 
“idiopatic familial lipemia” [239]. Later studies highlighted the cause of the 
similar diseases as a defect in post-heparin plasma activity and this 
phenotype was re-classified by Fredrickson as “type I hyperlipoproteinemia” 
[240]. The clinical traits include TG plasma levels >1000 mg/dL, very low or 
absent lipase activity, eruptive xanthomas, lipemia retinalis and pancreatitis. 
To date, two genetic diseases are associated with this phenotype: familial 
lipoprotein lipase deficiency (MIM 238600) and familial apolipoprotein C-II 
deficiency (MIM 207750) [173].  
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Familial LPL deficiency is a rare inherited disease (1:100,000 subjects) [173]. 
To date about sixty different mutations have been identified [241, 242]. Most 
of the loss of function mutations are in the exons 4,5 and 6 and they lead to 
major structural defects in LPL protein [33]. Mutant proteins are either 
degraded intracellularly or result in truncated forms that can be secreted but 
display no catalytic activity. The plasma lipid profile in carriers is consistent 
with Type I dyslipidemia [33, 243]. The severity of hypertriglyceridemia varies 
with the dietary fat intake. Although chylomicron accumulation is the main 
feature of LPL deficiency, several studies have shown that VLDL clearance is 
also impaired and contributes to the overall phenotype [244]. Hepatomegaly 
and xanthomas are typical traits and the latter are a consequence of lipid-
loaded macrophages accumulation [245]. Fat accumulation is not altered in 
these subjects but the FA composition is abnormal and shows increased 
content of monounsaturated FA [246, 247]. The composition is consistent with 
increased de novo lipogenesis, probably a compensatory response to 
reduced hydrolysis of diet-derived TG [247].  
In addition to complete LOF mutations, some mutations lead to reduced 
activity and translate in milder clinical phenotype. The common mutation 
N291S in exon 6 induces a partial loss of TG activity (~50%) [248]. It has 
been associated with decreased HDL-C and increased TG in subjects with 
familial combined hyperlipidemia (FCHL)[248] and with increased TG levels, 
non-HDL cholesterol and decreased HDL-C levels in subjects with familial 
hypercholesterolemia heterozygotes (FH) [249].  
The −93G promoter allele has been identified in different populations 
(Americans, Africans, Caucasians) [250]. It is associated with ~ 40 % 
reduction in LPL activity [250, 251]. In Caucasians T-93G is in linkage 
disequilibrium (LD) with another common variant, D9N. Subjects who carry 
the −93G/9N haplotype show decreased HDL-C, increased TC and TG and 
have increased risk of CVD, obesity and type II diabetes [252, 253]. This 
observation was not confirmed in another study in African carriers, where T-
93G was associated with mildly decreased TG levels [254]. 
Several common polymorphisms in LPL gene have been identified. The most 
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studied are HindIII and S447X that have been associated with TG and HDL-C 
concentrations [252, 255-258]. The directionality of the association is not clear 
and it has not been confirmed in all the populations investigated [259, 260] . 
Finally, HindIII has been positively associated with body mass index in obese 
subjects [261, 262].  
In the general population, LPL levels in pre-heparin plasma have been 
proposed as a marker of metabolic syndrome [263-267]. Metabolic syndrome 
is a cluster of conditions including high blood pressure, hyperglycemia, 
increased body mass index (BMI) and central obesity, and dyslipidemia. LPL 
mass in plasma do not vary with age and gender but can be affected by other 
metabolic factors. Ex vivo analysis of human plasma has shown that TG is 
normally associated with TG-rich lipoproteins in the postprandial space and 
promotes their catabolism [268]. Reduced levels of LPL thus impair 
postprandial lipoproteins clearance and are inversely correlated with the 
concentration of TG [269]. Human studies demonstrated that LPL levels are 
also inversely correlated with, oxidative stress and severity of metabolic 
syndrome [263, 266]. In diabetic subjects, LPL levels are decreased [265]. 
This is partially explained by the fact that LPL has been associated with 
insulin sensitivity [264].  
Hepatic Lipase 
 
The role of HL in metabolic disease is controversial. Genetic HL deficiency is 
strongly associated with cardiovascular disease, that represents the main 
cause of mortality in this population  [195]. However, the relationship between 
HL activity and CVD is not clear and different studies have supported a 
potential pro- or anti-atherogenic potential. At the physiological level, HL 
activity promotes the catabolism of mature, TG-rich HDL. This leads to a net 
reduction of circulating HDL-C levels and to the parallel regeneration of small 
HDL particles. In addition, HL is also responsible for the conversion of VLDL 
into IDL and LDL and the density of lipoproteins increases with this process.  
The combined reduction of HDL-C levels and increase of dense LDL particles 
are known risk factors for CVD. As a consequence, HL activity has been 
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expected to increase the risk for atherosclerosis [270-272]. 
Surprisingly, data from animal studies indicated that HL-deficient mice do not 
have increased atherosclerosis [273] and in apoE-KO background it seems to 
be protective [274]. Furthermore, HL expression ameliorates the lipid profile 
and aortic cholesterol accumulation in mice on high cholesterol diet [192, 275] 
[119]. HL deficient mice seem to be less susceptible to diet-induced obesity 
[276] and this effect seems to be directly mediated by its lipolytic activity [277]. 
In humans, HL deficiency is a very rare recessive disease. To date twelve 
patients from six families have been detected [152, 278-281]. The first patient 
with genetic HL deficiency was identified in 1982 in a Canadian family. Its 
clinical phenotype was characterized by hypertriglyceridemia, eruptive 
xanthomata and pancreatitis [278, 279, 282]. This phenotype is not very 
consistent across different mutations and even in the same family seems to 
be very variable. Plasma TG levels are normal to high and pancreatitis does 
not always occur. The very common feature of HL is an abnormal TG 
enrichment in LDL and HDL particles [282]. As a consequence of abnormal 
VLDL metabolism, these particles display abnormal migration when separated 
by charge on agarose gel and VLDL are retained in  position [282]. HL 
deficient lipoproteins display a Cholesterol:Triglycerides ratio of 1:1 [282-
284] and when analyzed by FPLC they display an abnormal size pattern.  
ApoB and HDL-C plasma levels are often increased and HDL-C can represent 
up to 50% of the total cholesterol pool [282]. The overall phenotype is a result 
of impaired hydrolysis of triglyceride (and phospholipid) in lipoproteins and 
reduced uptake of remnants by the liver [283]. 
Heterozygous subjects have a 50 %reduction in post-heparin plasma hepatic 
lipase activity. The lipid profile is variable, some carriers have a normal 
lipoprotein composition whereas others display TG enrichment [282, 284, 
285]. 
HL deficiency is inversely correlated with HDL-C levels both in the general 
population and in carriers of HL mutations [286, 287]. Women display a lower 
plasma HL activity compared to men and this has been proposed as one of 
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the possible explanations for gender-dependent differences in HDL-C levels 
[288, 289]. The sibling-pair linkage analysis of different populations of 
normotriglyceridemic Caucasians revealed that variants in HL locus 
accounted for 25% of the total interindividual variation in plasma HDL-C levels 
[290, 291].  Sequencing analysis of selected individuals from this population 
allowed identification of four polymorphisms in HL promoter region (−250 G-
to-A, −514 C-to-T, −710 T-to-C, and −763 A-to-G)[291]. Association analysis 
of the plasma lipid and lipoprotein levels revealed a small effect of the -514 
CT genotype on plasma HDL-C and apolipoprotein AI levels among men but 
not in women. Men carrying the TT genotype had very high plasma HDL-C 
and apolipoprotein AI levels. No effect on total cholesterol or triglyceride 
concentrations was observed [291]. In the San Antonio Family Heart Study, 
maximum-likelihood complex segregation approach lead to the identification 
of a major locus effect on low HDL-C allele, and heritability for plasma HDL-C 
levels. Linkage analyses however excluded tight linkage between the 
detected major locus and markers for HL locus [290].  In two further studies 
on male coronary artery disease (CAD) patients, the polymorphism in HL 
promoter was highly associated with lower HL activity (-25% in Heterozygotes 
and 50% in homozygotes) [292, 293]. The variants were more common in 
individuals with CAD than controls [294]. However this finding has not been 
confirmed in other studies [295]. The rare haplotype of the hepatic lipase gene 
promoter was observed to be more common among African Americans and 
Japanese Americans than among Caucasians [295-298]. C-514T 
polymorphism has been associated with increased obesity in Chinese boys 
but not girls [299].  
Multiple studies demonstrated a positive correlation between HL activity, 
diabetes and central obesity [300-304]. In obese subjects, the fraction of 
smaller, denser LDL, and mature HDL is decreased [286,249, 301, 305] and 
this lipoprotein profile can be normalized by weight loss [83]. Interestingly, 
data from the look AHEAD GWAS study indicated that in diabetic obese 
subjects LIPC (-105 A-to-T) single-nucleotide polymorphism was significantly 
associated with HDL-C and triglyceride changes with intensive lifestyle 
intervention [302]. 
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Endothelial Lipase 
 
Since it was cloned in 1999, EL has been recognized as major regulator of 
HDL levels in animal studies.  The first evidence of a relationship between EL 
activity and HDL levels in humans was observed in 2002 [306]. In this study 
20 unrelated subjects with HDL-C levels greater than the 90th percentile were 
recruited and the EL gene was sequenced. 17 polymorphic sites in EL were 
found and 6 potentially functional variants were identified (four amino acid 
changes Gly26Ser, Thr111Ile, Thr298Ser, and Asn396Ser, and 2 in the 
promoter 303A/C and 410C/G). The occurrence of these variants was then 
tested in 176 black controls, 165 white controls, and 123 whites with high 
HDL-C. Results indicated that Thr111Ile variant was the most common and 
was not directly associated with HDL-C levels. Interestingly, Gly26Ser, 
Thr298Ser, and 303A/C were found in the black and high HDL-C white 
cohorts but were absent in the control white group, thus indicating a possible 
functional association for these SNPs [306].  
Further studies lead to the identification of several other variants in LIPG 
(table I-4 and HGMD database [314]) and GWAS studies supported the 
association between SNPs in the LIPG locus and HDL-C levels [295, 307-
314]. Although while for some of the cited variants results from different 
populations are not consistent, the overall association between EL gene and 
HDL-C levels seems established. Several epidemiologic studies have clearly 
shown an inverse correlation between HDL-C levels and CVD risk [315, 316]. 
This association seems to be independent of other risk factors and it has been 
consistently reported in different populations [317-319]. Given this evidence, 
LOF mutations in LIPG were expected to induce a reduction in CVD risk. 
Surprisingly, studies aimed to determine the association between CVD and 
LIPG genetic variants did not give clear results. In the Lipoprotein and 
Coronary Atherosclerosis Study, (LCAS) patients with the missense variant 
c.111 C-to-T displayed increased HDL-C, apoC-III and higher HDL-C/LDL-C 
ratio. However, no significant association between the SNP and progression 
of coronary lesions was observed during the 2.5-year follow-up period [218]. A 
similar result has been observed in a study in 1138 CAD cases and 2237 
matched controls from the EPIC-Norfolk cohort [320] and in a Danish study on 
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three different populations of patients with CHD (988 subjects from the Diet, 
Cancer, and Health study, 241 subjects from the Nurses' Health Study, and 
262 subjects from the Health Professionals Follow-up Study) [321]. In both 
these two latter studies, no association between LIPG variants and CVD was 
reported.  
A study on 265 Chinese patients with CAD and matched control healthy 
subjects, the Thr111Ile variant was found to be associated with decreased 
risk of CAD [322]. In contrary, three studies on independent cohorts and one 
study on Japanese subjects showed a positive correlation between LIPG 
variants and incidence of CVD and stroke, respectively [323- 326]. 
Furthermore, results from a Mendelian randomization study indicated that a 
single nucleotide polymorphism in LIPG (Asn396Ser) selectively increased 
HDL-C but these changes did not result in any reduction in the risk of 
myocardial infarction [327]. 
It has to be noted that most of the studies tested the association of CVD 
markers with known coding mutations in LIPG. Furthermore, all studies 
identified a high percentage of carriers of the relative common Thr111Ile 
variant. Interestingly, Khetarpal and colleagues in 2011 observed that the 
229T-to-G regulatory variant in the untranslated 5’ region induced a decrease 
in EL promoter activity. This variant was in LD with the more common 
Thr111Ile variant. Since Thr111Ile variant in vitro does not seem to affect EL 
enzymatic activity, it is possible that the association between this variant and 
high HDL-C levels may be mediated by the presence of 229T-to-G regulatory 
variant. This haplotype may partially explain the contradictory results 
observed in the previous studies [328].   
The relationship between EL protein mass and HDL-C levels has been 
corroborated by several animal studies [213, 217, 329]. The first study that 
showed that correlation in humans was conducted by Badellino and 
colleagues in 2006 [330]. In this study, 858 asymptomatic subjects with a 
family history of premature CAD were recruited from the Study of the Inherited 
Risk of Atherosclerosis (SIRCA) population. Authors demonstrated that EL 
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concentrations in pre- and post-heparin plasma were negatively associated 
with HDL-cholesterol levels [330]. Furthermore, EL mass was positively 
correlated with small HDL3 concentrations and negatively correlated with 
large, mature HDL particles. No association was observed between EL and 
apoA-I levels [330]. Interestingly, in this study, EL mass was found to be 
associated with markers of metabolic syndrome and subclinical 
atherosclerosis such as the coronary artery calcification index [330].  
This observation along with strong data from in vitro and in vivo studies 
supports a positive association between EL and features of metabolic 
syndrome such as inflammation, lead to further investigations.  
Very early studies on EL structure and regulation already highlighted that 
LIPG mRNA levels were upregulated by inflammatory cytokines such as TNF-
 and IL-  [95, 224]. The physiological meaning of EL upregulation is still not 
clear. It is well known that the other two plasma lipases (HL and LPL) are 
downregulated in the inflammatory state and it has been proposed that the 
concerted activity of all lipases may contribute to fulfill the cellular needs for 
HDL-derived FA during the inflammation [331, 332]. EL overexpression during 
inflammation likely explains the decrease in HDL-C levels observed in acute 
inflammation [333].  In a study on 74 moderately obese men, EL plasma mass 
was positively correlated with obesity, fasting plasma insulin, and plasma 
CRP, IL-6, and sPLA(2)-IIA concentrations. Interestingly, EL mass association 
with inflammation was independent of fat accumulation, LPL-activity or 
lipoprotein plasma levels [334].  
Another study in healthy subjects from the SIRCA population demonstrated a 
strong positive correlation with C-reactive protein, interleukin-6, soluble TNF 
receptor II, soluble intercellular adhesion molecule 1, and leptin and an 
inverse correlation with adiponectin. Furthermore, experimentally-induced 
endotoxemia directly induced an increase in EL concentrations [228]. Finally, 
in a study on 80 sedentary men and 14 women post-heparin plasma EL 
concentration has been demonstrated to be positively associated with BMI, 
visceral adipose tissue, plasma cholesterol and TG. In this study, fat samples 
were collected from women during hysterectomy surgery. The analysis of 
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mRNA levels in visceral and subcutaneous adipose tissue revealed no 
difference in EL expression in these two tissues and demonstrated a relative 
103 higher expression of LPL.  
Interestingly, variants in EL gene have been associated with interindividual 
variability in HDL-C levels in response to physical exercise. It is known that 
exercise training can increase HDL-C levels, whereas inactivity promotes a 
pro-atherogenic lipid profile. In two studies on carriers of common LIPG 
variants, it has been demonstrated that EL genotype negatively affects 
exercise-induced increase in HDL-C levels [335, 336]. 
It has been proposed that EL may be associated with the development of 
insulin sensitivity. In humans, EL is positively associated with several markers 
of insulin resistance [330, 334] and different studies showed that EL plasma 
levels are increased in diabetic patients [337-339]. In vitro studies gave 
controversial results. In an early study in rat hepatocytes, insulin had no effect 
on endothelial lipase synthesis [340], whereas in a more recent study on 
human aortic endothelial cells, insulin significantly reduced EL mRNA and 
protein. Consistently, in the latter study, diabetic patients treated with insulin 
but not oral anti-diabetic drugs, displayed a significant reduction in EL mRNA 
and protein [341]. 
Taken altogether results from individuals with metabolic syndrome indicate a 
strong association of EL with several markers of the disease. The correlation 
between plasma levels of EL and cytokines is strong and independent of other 
traits such as lipoprotein profile both in obese subjects and healthy 
individuals. This suggests that inflammation alone may be sufficient to induce 
EL increased expression. However, although inflammation is a condition 
commonly associated with obesity and metabolic syndrome, it is still unclear if 
that is an early event in the pathogenesis of the disease. As a consequence, 
even if EL expression may be sustained by inflammation, other factors may 
contribute for the EL upregulation in subjects with metabolic syndrome.  
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Missense mutations 
dbSNP 
number 
Nucleotide 
change 
Amino 
acid 
change 
Effect on 
function 
Phenotype Reference 
rs9963243 c.76G>A p.G26S 
 Lipase 
activity 
 HDL-C 
[306, 342, 
343] 
NA c.82G>A p.E28K 
=Lipase 
activity 
(predicted) 
NA [343] 
 
rs200103565 
 
c.115A>C p.K39Q 
=Lipase 
activity 
(predicted) 
 HDL-C [344] 
 
rs375653841 
 
c.155A>G p.N52S 
 Lipase 
activity 
NA [343] 
 
rs61729804 
 
c.160C>T p.R54C 
 Lipase 
activity 
NA [343] 
 
rs61729804 
 
c.218C>T p.P73L 
 Lipase 
activity 
NA [343] 
rs2000813 c.332C>T p.T111I 
= Lipase 
activity 
= HDL-C 
=  CAD 
Stroke 
diabetic 
retinopathy 
[218, 306, 
320-326, 
328, 338, 
343, 345, 
346] 
rs111384586 c.346G>A p.A116T 
 Lipase 
activity 
(predicted) 
 HDL-C [346] 
NA c.388C>T p.L130F 
 Lipase 
activity 
(predicted) 
 HDL-C [347] 
NA c.526G>A p.G176R 
 Lipase 
activity 
(predicted) 
=  HDL-C [346] 
NA c.586G>A p.G196R 
 Lipase 
activity 
 HDL-C [347, 348] 
NA c.660C>G p.H220Q 
 Lipase 
activity 
 HDL-C [347, 348] 
NA c.716T>C p.I239T 
 Lipase 
activity 
(predicted) 
=  HDL-C [346] 
NA c.817G>T p.E273 
 Lipase 
activity 
(predicted) 
 HDL-C [349] 
NA c.1012A>C p.T338P 
 Lipase 
activity 
NA [343] 
NA c.1024A>G p.M342V 
 Lipase 
activity 
(predicted) 
=  HDL-C [346] 
NA c.1162G>T p.E388* 
 Lipase 
activity 
 HDL-C [347] 
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rs181279169 c.1166G>A p.R389Q 
 Lipase 
activity 
NA [343] 
rs138438163 c.1171G>A p.E391K 
 Lipase 
activity 
 HDL-C [344] 
rs77960347 c.1187A>G p.N396S 
 Lipase 
activity 
 HDL-C [348] 
rs117623631 c.1486A>G p.R476W 
 Lipase 
activity 
=  HDL-C [348] 
NA c.1486A>G p.T496A 
 Lipase 
activity 
(predicted) 
 TC [350] 
 
rs113235863 
 
c.1501T>C p.501R 
 Lipase 
activity 
(predicted) 
 HDL-C [346] 
 
 
Regulatory/intronic mutations  
dbSNP 
number 
Mutation 
Type 
Codon number 
Codon 
change 
Phenotype Reference 
rs34474737 Regulatory 
-24 rel 
to initiation codon 
T-G 
Decreased 
promoter activity. 
LD with 
111C-T 
[328] 
rs3744841 Regulatory 
+482 relative 
to termination 
codon 
G-A HDL-C [351] 
rs3744841 
 
Regulatory 
-384 relative 
to transcription 
initiation site 
A-C 
HDL-C 
CAD 
[320, 325, 
352, 353] 
NA Intronic 
 
+ 2864 relative 
to initiation codon 
 
T-C HDL-C [354] 
NA Intronic 
+ 42 relative 
to initiation codon 
C-T HDL-C [354] 
Deletions 
Nucleotide deletion Phenotype Reference 
c.342delA  HDL-C [346] 
c.388delC  HDL-C [355] 
 
Table I-4 Summary of genetic variants identified in LIPG.  
Data were obtained from specific references and HGMD database  [314].  
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Aim 
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Plasma triglyceride lipases, lipoprotein lipase (LPL), hepatic lipase (HL) and 
endothelial lipase (EL) are secreted enzymes that bind to the endothelial 
surface and catalyze the hydrolysis of lipids on circulating lipoproteins [1]. The 
released fatty acids are then available for uptake by peripheral tissue where 
they can exert trophic or modulatory functions. As a consequence, the 
concerted activity of the three lipases has profound effects on plasma and 
tissue lipid metabolism. 
The specificity and physiological activity of LPL and HL have been extensively 
explored in vivo and in vitro. LPL preferentially hydrolyzes triglyceride (TG) in 
chylomicrons and VLDL, whereas HL hydrolyzes TG and phospholipid (PL) in 
HDL and LDL [2, 33].  The study of human carriers of LPL and HL deficiency 
highlight the importance of these lipases on lipoprotein and tissue metabolism 
[173]. Furthermore, clinical studies have shown that lipase activity is tightly 
linked to the pathogenesis of metabolic disorders such as dyslipidemia, 
diabetes and obesity [263-267, 300-304]. 
EL is the most recently identified member of the plasma triglyceride lipase 
family [89, 90]. Analysis of EL substrate specificity revealed that EL 
hydrolyzes both PL and triglycerides TG on lipoproteins and has a relatively 
higher specificity for PL compared to TG [89, 90, 211]. Since it was cloned in 
1999, EL has been shown to be a major regulator of HDL-C levels both in 
vitro and in vivo [89, 90, 218]. Consistent with its biochemical profile, in 
humans, genetic variants for EL are associated with increased HDL-C levels 
but these changes do not translate into a reduction in CVD risk (Table I-4). 
Given the established inverse correlation between HDL-C and cardiovascular 
disease, early human studies have focused on better understanding the 
relationship between EL activity and a pro-atherogenic lipid profile. These 
studies consistently demonstrated a strong correlation between EL mass and 
several traits of metabolic syndrome such as body mass index (BMI), visceral 
adiposity, inflammation, insulin resistance and atherogenic lipoprotein levels 
[228, 229, 330]. However, metabolic syndrome is by definition a 
heterogeneous condition, and the causal relationship linking EL to one of 
multiple traits is still unknown.  
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Furthermore, very little is known about the role of EL in apoB-containing 
lipoproteins and tissue lipids. In vitro data indicated that EL can hydrolyze PL 
and TG in apoB containing lipoproteins [211, 222]. EL overexpression 
promotes the clearance of LDL particles and translates in significantly 
reduced LDL, VLDL, apoB, total cholesterol, TG and PL levels [216]. In 
contrast, EL deficiency is associated with increased levels of non-HDL 
cholesterol and apoB-containing lipoproteins [356]. The physiological 
significance of EL-mediated hydrolysis of TG-rich lipoproteins is not known. 
LPL is thought to be the main enzyme responsible for the catabolism of TG-
rich lipoproteins [2]. However, LPL deficiency in humans is not associated 
with reduced adiposity and it has been proposed that EL could provide an 
alternative pathway for free fatty acid uptake into adipose tissue [173, 357].  
The Aim of this thesis is to assess the role of EL in TG-rich lipoprotein 
metabolism and to investigate the relationship between EL activity, hepatic 
function and the development of key traits of metabolic syndrome in vivo. 
This general aim will be pursued through three specific aims 
 Specific Aim 1: Establishing the effect of EL deficiency on the onset of 
clinical hallmarks of metabolic syndrome in vivo.  
Metabolic syndrome is a cluster of modifiable/ risk factors including 
obesity, hypertriglyceridemia, and hyperglycemia. These conditions 
can be efficiently induced in mice by feeding a long-term high-fat diet. 
We took advantage of the availability of a mouse model of EL 
deficiency to compare the onset and severity of metabolic syndrome 
traits in the presence or absence of EL activity. The ultimate goal of 
this experimental set was to clarify the directionality of the association 
between increased EL levels and metabolic syndrome. 
 
 Specific Aim 2: Defining the role of EL in plasma TG-rich lipoprotein 
metabolism. 
Using a similar experimental design, the plasma lipoprotein profile of 
WT and EL-deficient mice on regular chow diet and in response to a 
high fat diet was extensively characterized. To understand the basis of 
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EL-mediated TG hydrolysis in the setting of a high fat diet, hepatic TG 
production, clearance and tissue fatty acid (FA) uptake have been 
studied. 
Finally, EL and LPL have distinct, but complementary tissue distribution 
and lipid substrates. In vitro experiments have been specifically 
designed to assess whether there is a cooperative effect of both 
lipases on TG-rich lipoprotein metabolism. 
 
 Specific Aim 3: Defining the impact of EL deficiency on liver lipid 
metabolism. 
Hydrolysis of TG-rich lipoproteins not only affects plasma lipoprotein 
metabolism but determines the availability of FA in peripheral tissues 
and contribute to the regulation of de novo lipogenesis. Alterations in 
FA utilization by the liver are associated with the development of fatty 
liver disease [221]. EL, but not LPL, is expressed in adult liver and may 
contribute to hepatic lipid sensing and regulation of hepatic lipid 
storage. To test this hypothesis, the hepatic lipid accumulation in EL 
deficient and WT mice was evaluated and the expression levels of key 
genes involved in the regulation liver lipid metabolism was determined. 
This specific aim is focused on understanding the effect of EL 
deficiency on liver lipid homeostasis. 
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1 In vivo procedures 
 
Animal care and diet treatment 
 
All the animal experiments were performed at the University of Pennsylvania. 
All the procedures were performed according to the regulations and with the 
prior approval of the Institutional Animal Care and Use Committees of the 
University of Pennsylvania (IACUC, protocol number 803056).  
Male C57BL/6 (or wild-type, WT) were obtained from Jackson. Male 
endothelial lipase (EL)-KO mice on a C57BL/6 background were previously 
described [213]. All mice were housed in a pathogen-free animal facility with a 
daylight cycle from 07.00 AM to 7.00 PM. Animals had access to food and 
water. For the characterization of the baseline phenotype, mice were fed a 
regular chow diet (Lab Diet). For experiments that required the induction of 
the metabolic syndrome phenotype, 10 weeks old mice were fed a high fat 
diet (D12451- Open Source Diets- 45% Kcal from fat) for 12 weeks.  
Non-fasted body weights were measured weekly, beginning at the time of 
weaning. During the diet treatment, the leftover food in each cage was 
weighted weekly. The calculation of the daily food consumption was done by 
dividing the weight of the consumed food in each cage by the number of 
animals in the cage.  
Blood was collected either via retro-orbital bleeding or tail vein bleeding (see 
single protocol) under isoflurane anesthesia, using EDTA containing- capillary 
tubes.  
When euthanasia was required by the experimental design, mice were 
sacrificed by cervical dislocation under deep isoflurane anesthesia.  
Metabolic phenotyping and activity measurements 
 
Body composition (lean and fat mass) was measured by DEXA (dual-energy 
X-ray absorptiometry) scan and magnetic resonance imaging by the Mouse 
Phenotyping, Physiology and Metabolism Core at the University Of 
Pennsylvania School Of Medicine, according to the method described by 
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Varela and colleagues [358].  Metabolic rates were measured by indirect 
calorimetry in open-circuit oxymax chambers, using the the Comprehensive 
Lab Animal Monitoring System, CLAMS (Columbus Instruments, Columbus, 
OH, USA). Mice were housed singly in sealed, open flow chambers and 
maintained at 24  °C under a 12-h light–dark cycle (light: 07.00 AM-7.00 PM). 
Food and water were available ad libitum. All the mice were acclimated to 
monitoring cages for 24  h before the initiation of experiment. To calculate 
oxygen consumption (VO2), carbon dioxide production (VCO2) and RER 
(ratio of VCO2 to VO2), the gas concentrations were measured in the 
incurrent and excurrent gas flow. VCO2, VO2 and calculated heat were 
normalized to lean mass, for each animal.At 12 weeks mice were sacrificed 
and the different fat depot (inguinal, subcutaneous and brown fat) were 
collected and weighted.  
Glucose Phenotyping 
 
Glucose Tolerance Test 
 
The glucose tolerance test (GTT) is a standardized method to measure the 
glucose clearance from the circulation, after an acute loading. This test is 
used in both mice and humans to determine potentially sub-pathological traits 
that may predispose to frank insulin resistance. Mice were fasted overnight, 
weighted and bled via tail vein to measure the baseline glycaemia. Each 
mouse received an intraperitoneal bolus of sucrose (10 uL/g of body weight of 
a 20% sucrose solution in PBS). Blood glucose was measured at 15, 30, 60, 
90 and 120 min after injection, via the tail vein with the BREEZE 2 glucometer 
(Bayer).  
Insulin Tolerance Test 
 
The insulin tolerance test (ITT) is a standardized method to measure the body 
tissue responsivity to insulin. Mice were fasted for 4 hours, weighted and bled 
via tail vein to measure the baseline glycaemia. Each mouse received an 
intraperitoneal bolus of insulin (Humalin-R, 0.75 U/Kg body weight). Blood 
glucose was measured at 15, 30, 60 and 120 min after injection, via the tail 
vein with the BREEZE 2 glucometer (Bayer). 
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Determination of systemic inflammatory response 
 
In order to evaluate the inflammatory response in WT and EL-KO mice, a 
model of experimentally-induced low-dose endotoxemia was used. 
Lipopolysaccharide (LPS) injections are used in mice and humans in the 
literature as a model for low level inflammation as seen in obesity, 
atherosclerosis, and other inflammatory diseases [359, 360]. This procedure 
induces a transient mild inflammatory response without causing infection and 
it’s thus typically well tolerated by the animals. WT and EL-KO mice were 
maintained at 24  °C under a normal 12 h light–dark cycle. Food and water 
were available ad libitum. In order to permit the determination of baseline 
cytokine levels, prior to LPS injection blood was collected via tail vein 
bleeding. Mice were then intraperitoneally injected with LPS solution in PBS at 
a dose of 0.5 mg/kg (Sigma Aldrich). Mice were monitored every hour to 
check their well-being. Blood was collected via tail vein bleeding at one and 
three hours after injection, using EDTA-containing capillaries. Mice were then 
euthanized as described previously. Blood was spun and plasma was 
collected for cytokines determination. TNF-  plasma concentration was 
determined using the mouse TNF-alpha Quantikine ELISA Kit (R&D systems). 
Oral Fat Tolerance Test  
 
In order to determine post-prandial TG clearance in mice the Oral Fat 
Tolerance Test was performed. WT and EL-KO mice on high fat diet or chow 
(n=6 per group) were fasted overnight. During this period were maintained at 
24  °C under a normal 12 h light–dark cycle and had access to water. Prior to 
gavage blood was collected to determine the baseline TG plasma levels. Mice 
were then weighted and gavaged with 10 uL/g of body weight of olive oil 
(Sigma Aldrich). After gavage, blood was collected at 1, 3, 5 and 7 hours via 
retro-orbital bleeding, using EDTA-containing capillaries. Blood was spun and 
plasma was collected for TG determination, FPLC and agarose gel 
electrophoresis analysis. The TG content was measured by colorimetric 
enzymatic assays in a 96 wells plate (Infinity Triglycerides reagents, Thermo 
Fisher). 
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In vivo clearance kinetic experiments  
 
Isolation and labeling of human TG-rich lipoproteins 
 
TG-rich lipoproteins (TRL) were purified by sequential ultracentrifugation of 
the plasma of non-fasted anonymous healthy volunteers. Plasma was isolated 
from 200 ml of blood. It was then transferred to ultracentrifugation tubes and a 
layer of KBr solution (density=1.006 g/L) was added on top. The tubes were 
sealed and ultracentrifugated in a Beckman XL590 Ultracentrifuge (Beckman 
Coulter) using a 70.1 Ti rotor (Beckman Coulter) at a speed of 40,000 RPM 
for 18 hours. At the end of the run, TG-rich lipoproteins, including VLDL, CM 
and remnants, that are characterized by a density <1.006 g/L floated on the 
top of the tube. Lipoproteins were then collected and the total protein content 
was measured by BCA assay (Pierce BCA Protein Assay Kit, Thermo 
Scientific) and further processed for radioactive labeling. 
125I protein labeling: Dialyzed human TG-rich lipoproteins were labeled with 
125I by the iodine monochloride method [361]. Lipoproteins were then dialyzed 
against PBS to remove excess of non- incorporated 125I. For direct 125I 
labeling, 1.5 mg of of TRL in PBS were iodinated with 1 mCi of 125I, 300 ul of 1 
M glycine, and 150 uL of 1.84 M NaCl / 2.84 uM ICl solution, vortexed and 
applied to a PG510 desalting column (Amersham Biosciences) that was pre-
equilibrated with 0.15 M NaCl / 1 mM EDTA solution. Iodinated proteins were 
eluted in NaCl/EDTA solution to a final volume of 2 mL. They were then 
dialyzed against PBS and protein concentration was assessed by BCA. 125I 
activity was determined by gamma counting (Packard Cobra II Auto5 Gamma 
counter).   
3H-TO-labeling: TRL were labeled with [3H] Triolein (TO), using cholesteryl 
ester transfer protein to facilitate the incorporation [362]. Briefly, 3 mg of TRL 
protein was used for labeling with 0.5 mCi of 3H-TO (Perkin Elmer). 0.5 mCi 
of 3H-TO in toluene was dried down under a nitrogen and resolubilized in 150 
uL of ethanol. 3H-TO solution and lipoprotein depleted human plasma (100 
mg protein / 3 mg TRL protein) were added to TRL and the resulting mixture 
was incubated at 37 °C overnight. Labeled TRL were then subjected to a 
“rinse” ultracentrifugation in the same conditions described above. This step 
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permits the re-floctation of TRL and removal of excess of non-incorporated 
3H-TO. TRL were then collected, dialyzed against PBS, and fractionated by 
FPLC to measure TG and 3H activity in the VLDL-CM fractions relative to 
unincorporated 3H activity. Activity was determined by scintillation counting 
(Beckman LS 6500 Scintillation System). 
In vivo clearance determination 
 
In vivo experiments were designed to determine the plasma lipolysis rate of 
TRL-associated TG and particle clearance from the circulation [361, 363].  
Prior to the initiation of the experiment mice were fasted 4 hours and bled to 
determine the baseline lipids. They were then injected with dialyzed 3H or 125I 
labeled TRL were administered by intravenous tail vein injection into WT and 
EL-KO mice. Mice were bled at 1, 3, 5, 10 and 15 minutes after TRL 
administration. Mice were euthanized at 15 minutes after injection as 
previously described and tissues collected.  
Plasma 3H and 125I activity at each timepoint were determined using 
scintillation counting and gamma counting, respectively (Beckman LS 6500 
Scintillation System and Packard Cobra II Auto5 Gamma counter). The 
relative 3H activity remaining the in circulation was calculated by normalizing 
the activity from each timepoint by that of the 1 minute timepoint for each 
mouse.  The fractional catabolic rates were calculated with the SAAM II 
program (SAAM Institute) by fitting a biexponential curve to the [125I] and [3H] 
counts normalized to the 1-minute time point. The differential uptake of 
labeled 3-H FA in each tissue was determined by scintillation counting of ~150 
ug of homogenized tissue in PBS. The results were expressed as activity/ mg 
of tissue and normalized to the 1-minute time point.  
In vivo reconstituted HDL clearance 
 
rHDLs containing 18:1-12:0 Top Fluor PC, UC and apoA-I were  prepared 
according to the cholate dialysis method. Human HDL were isolated 
sequential ultracentrifugation of the plasma (d<1.21 g/L) and apoA-I was 
purified using the cold ethanol precipitation method ( ~95% purity by SDS-
PAGE) [364]. The apoA-I was combined with palmitoyl-2-oleoyl-sn-glycero-3-
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phosphocholine (POPC, Sigma Aldrich), non-esterified cholesterol (FC, Avanti 
polar Lipids), esterified cholesterol (CE, Avanti Polar Lipids) and Top fluor PC 
(1-palmitoyl-2-(dipyrrometheneborondifluoride)undecanoyl-sn-glycero-3-
phosphocholine, Avanti polar Lipids), using the sodium cholate dialysis 
method (weight ratio = 10.5: 0.3:0.3:1.5:1.2 mg for POPC:FC:CE:apoA-I: top 
FluorPC)[365]. After the additions, sodium cholate was removed by dialysis 
(dialysis tubes with molecular weight cut-off =12-14 kDa, spectra/Por, 
spectrum Lab). 0.2 mg of Top-Fluor PC were intravenously injected to each 
mouse and tissues were collected after 6 hours. 100 ug of tissue were 
homogenized and lipids were extracted according to the Folch method [366]. 
Lipids were then dried down and resuspended in 5% Triton X solution in PBS. 
Fluorescence was determined using a microplate reader (Synergy MX, 
BioTech). 
In vivo TG secretion  
 
Hepatic VLDL secretion was measured in WT and EL-KO mice (n=8) [367]. 
Briefly, mice were fasted for four hours and then administered the surfactant 
Pluronic acid (25 mg in 0.4 ml PBS) by intraperitoneal injection to inhibit 
peripheral lipolysis. Mice were bled at 0, 60, 120, and 240 minutes after 
Pluronic acid administration for plasma collection. Plasma TGs were 
measured at each timepoint with the Infinity Triglycerides reagent (Thermo 
Scientific) in 96 wells plates. 60 and 240 minute plasma samples were used 
for calculating the TG secretion rate by linear regression of the curved 
describing the measured concentration kinetic.  
Post-heparin plasma collection 
 
Post heparin plasma was collected from WT and EL-KO mice in order to 
measure the lipase activity against emulsion substrate (see section 3). Mice 
were weighted and then fasted for 4 hours. They were injected heparin 
solution via tail vein (300 units heparin/kg body weight). 5 minutes after 
injection blood was collected and centrifuged at 10,000 g for 10 min at 4°C to 
separate plasma.   
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2 Ex vivo analyses 
 
Histology 
Hematoxilin and eosin staining 
 
Hematoxylin and Eosin (H & E) staining is the most common staining 
technique in histopathology. This uses a combination of two dyes, 
Hematoxylin and Eosin that allow one to easily visualize nucleus and 
cytoplasmic inclusions in tissue sections. Immediately after euthanasia, 
tissues (liver, fat, skeletal muscle) from WT and EL-KO mice (n=6 per group) 
were collected, sectioned and fixed in a 4% paraformaldehyde solution at 4 
C overnight. Tissues were then dehydrated by equilibration with increasing 
concentrations of ethanol solution, and infiltrated with wax. The infiltrated 
tissues were embedded into paraffin wax blocks (Paraplast X-tra) and 
sectioned using a microtome (6 µM thickness) at the Histology and Gene 
expression Core of the University of Pennsylvania.  Prior to proceed to H&E 
staining, sections were deparaffinized in xylene, (10min X2) and rehydrated 
with distilled water. They were then stained with Hematoxylin (CAT 
Hematoxylin) for 3-5 min, rinsed with water and differentiated with acid alcohol 
(1% HCl in 70% alcohol). After washing slides were stained with Eosin (Edgar  
Degas Eosin) for 4 min. Slides were then dehydrated and differentiated with 
95% alcohol.  Slides were finally cleared by immersion in in xylene and 
mounted with mounting media (Permount). 
Adipocytes size and number characterization 
  
Images were acquired with a Leica DM4000B upright scope paired with 
a Spot RT/SE slider camera. For the adipocyte analysis, a total of 6 tissue 
specimens per group were processed. For each specimen, 3 images/section 
and 5 different sections were analyzed (15 images/specimen, 6 specimens 
per group). Images were acquired at a 200X magnification and then analyzed 
with Adiposoft software [368]. 
Oil red O staining 
 
Oil red O staining specifically marks lipid inclusions. The staining is based on 
the lipophily of the dye that permits a high affinity for neutral lipids. As a result, 
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stained lipids are red and the further counterstaining with hematoxylin confers 
nuclea a blue appearance.  To this purpose liver tissues from WT and EL-KO 
mice (n=6 per group) were collected immediately after sacrifice, fixed in 4% 
PFA for 1 hour and then cryopreserved by immersion in 30% sucrose solution 
over-night. Tissues were then embedded in OCT cryo-medium and frozen in 
liquid nitrogen.  The further processing of the specimen was performed at the 
Pathology Core of the Children’s Hospital of Philadelphia. 8 µM thickness 
sections were obtained using the cryotom (Thermo Scientific Microm HM 
560). Sections were air dried, rinsed with 60% isopropanol, stained with Oil 
Red O solution for 15 mins and rinsed again with 60% isopropanol. Nuclea 
were then counterstained with alum haematoxylin, slides were rinsed and 
mounted with acqueous glycerine for analysis. 
Images were acquired with a Leica DM4000B upright scope paired with 
a Spot RT/SE slider camera. 
Plasma and Tissue Lipid analysis 
 
Plasma levels of total cholesterol, HDL cholesterol, phospholipid, triglyceride 
and Non-Esterified Fatty acids were determined enzymatically by colorimetric 
and immunoturbidrimetric assays using Axcel clinical analyzer, unless 
indicated otherwise in the specific procedure. Non HDL cholesterol levels 
were calculated by subtraction of HDL-C levels to total Cholesterol levels. 
Tissue TG and cholesterol content was determined as follows. Frozen mouse 
liver samples were weighted and homogenized in PBS using a high speed 
mechanical homogenizer (TissueLyser II, Quiagen). Homogenized sample 
was diluted 1:50 with a solution containing 1% or 0.25% deoxycholate for 
assaying TG and cholesterol, respectively. Hepatic concentrations of 
cholesterol and triglycerides were then measured using commercial kits 
(Infinity Triglycerides and Infinity Cholesterol reagents, Thermo Fisher) and 
normalized per gram liver weight.  
FPLC fractionation of plasma lipoproteins 
 
Plasma lipoproteins were separated by Fast Protein Liquid Chromatography 
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(FPLC) with size exclusion method that separate lipoproteins according to 
their size. Columns were equilibrated with buffer before loading sample. Equal 
volumes of plasma from WT and EL-KO mice were mixed into two separate 
pools and injected into the column (GE AKTA Purifier 100, mounting 2 
Superose 6 Increase 10/300 GL columns).   
Phosphate buffer containing 0.15 M NaCl, 0,03% EDTA and 0,02% NaN3 was 
used as mobile phase.  Once in the column, the lipoprotein classes segregate 
by size, based on their ability to be retained in the gel pores. This principle 
determines the differential elution time of different lipoprotein subclasses. The 
elution profile was monitored by UV absorption at 280 nm. FPLC was 
performed at 0.3 mL/min constant flow rate for 84 minutes at room 
temperature. Fortysix fractions of 0.5 ml each were collected in 96 wells-plate 
and total cholesterol and TG content was measured in each fraction by 
colorimetric enzymatic assays (Infinity Cholesterol and Infinity Triglycerides 
reagents, Thermo Fisher). The apolipoprotein content of 150 uL of each 
fraction was determined by western blot (see specific procedure).  
Agarose gel Electrophoresis of Plasma lipoproteins 
 
Agarose gel electrophoresis is a well-established technique routinely used in 
clinical laboratories for screening lipoprotein abnormalities in plasma. It is 
based on the principles of zone electrophoresis and allows lipoproteins to 
separate based on charge and size. 2 uL of plasma from the OFTT 
experiment (pre, 3 and 7 hours time-points ) was loaded onto agarose gel 
(Titan Lipoprotein gels, Helena) and run in Barbital buffer (pH=8.5) at constant 
voltage for 50 minutes. At the end of the run, gels were dried in ventilated 
oven, stained with Fat-Red-methanol solution and images were acquired 
using ChemiDoc Imaging System (Biorad). Electrophoretograms are 
evaluated visually for the presence of quantitatively or qualitatively abnormal 
protein bands.  
Protein expression analysis  
 
Protein expression was analyzed by Western Blot. Depending on their nature, 
samples were pre-treated in different ways. For FPLC fractions 150 uL of 
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each fraction was dried down to a final volume of 20 uL using a personal 
evaporator at 37 °C (Genevac, SP Scientific). For liver protein analysis, frozen 
tissue was homogenized in RIPA buffer containing a complete set of protease 
inhibitors (Roche), using a high speed mechanical homogenizer (TissueLyser 
II, Quiagen). The homogenate was spun at 15000 rpm. The surnatant, was 
collected, protein content was determined by BCA assay (Pierce BCA Protein 
Assay Kit, Thermo Scientific) and 50 ug of total protein were loaded into the 
gel. Finally, for total plasma protein content, 1uL of sample was utilized. All 
samples were combined with NuPAGE LDS Sample Buffer and NuPAGE 
Sample Reducing Agent, according to the manufactures specifications. 
Samples were heated at 95  °C for 10 minutes to help denaturation and then 
run into gradient gels. All runs were conducted in presence of a pre-stained 
protein standard to verify the expected protein molecular weight (SeeBlue 
Plus2, Invitrogen). For apoB48 and apoB100 determination precast 3-8% Tris-
Acetate gels and tris-acetate buffer were used (Novex 3-8% Tris-Acetate Midi-
Gels and  Tris-Acetate SDS Running Buffer, Invitrogen). For other proteins, 4-
12 % gradient was used and the run has been conducted using 3-(N-
morpholino)propanesulfonic acid (MOPS) buffer (NuPAGE Novex Bis-Tris 
Gels and NuPAGE MOPS SDS Running Buffer, Invitrogen). Gels were run in 
the XCell SureLock apparatus and transferred to nitrocellulose membrane 
(Biorad) using the XCell II Blot Module with SDS and methanol containing 
transfer buffer (NuPAGE Transfer Buffer with 20% methanol, Invitrogen).  
The membranes were blocked over-night in 5% fat free milk (Thermo Fisher) 
and then immuno-blotted against target proteins. For this purpose the 
following antibodies were used. 
Primary antibodies: 
 Rabbit anti Apolipoprotein B48/100 (K23300R), Meridian Life Science,  
 Rabbit anti Apolipoprotein E (NB100-2040), Novus Biologicals  
 Mouse anti B-Actin, clone  AC-15 (A5441), Sigma Aldrich 
 Rabbit anti LPL, H-53 (sc-32885), Santa Cruz 
 Rabbit anti HL, H-70 (sc-21007), Santa Cruz 
 Goat anti SCD1, E-15 (sc-14720), Santa Cruz 
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 Rabbit anti human EL, was generated in the Rader lab against a 
peptide in the N-terminal region of EL [89].  
Secondary antibodies: 
 Goat anti rabbit IgG-HRP (sc-2030), Santa Cruz 
 Rabbit anti mouse IgG-HRP (sc-358914), Santa Cruz 
 Rabbit anti goat IgG-HRP (1721034), Biorad 
The detection was performed by incubation of immunoblotted membranes 
with Luminata Crescendo Western HRP substrate (EMD Millipore) and the 
image was obtained using ChemiDoc Touch Gel and Western Blot Imaging 
System and analyzed using Image Lab software (Biorad).  
Gene expression analysis 
 
Immediately after euthanasia tissues were collected and snap frozen in liquid 
nitrogen to preserve nucleic acids. Total RNA was extracted from tissues 
using Trizol (Thermo fisher). Tissues were homogenized in Trizol with a high 
speed mechanical homogenizer (TissueLyser II, Quiagen) and RNA was 
extracted with chlorophorm/isopropanol method according to the 
manufacturer specifications (Trizol, Thermo fisher). RNA was quantified by 
spectrophotometric absorbance determination at 260 nm (Take3 Micro-
Volume Plates. BioTek). Absorbance at 230 and 280 nm was also measured 
to determine nucleic acid purity. 0.1 μg of RNA was retrotranscripted in cDNA 
using High-capacity cDNA Reverse Transcription Kit (Applied 
Biosystem).  The gene expression was evaluated through quantitative Real 
Time PCR, using pre-optimized reagent and QuantStudio 7 Flex Real-Time 
PCR System (Applied Biosystems). Briefly, the reaction mixture included a 
mix of unlabeled PCR primers and a TaqMan probe with FAM dye label 
(Applied Biosystems- TaqMan Gene Expression Assays), and TaqMan Fast 
Advanced Master Mix (Applied Biosystems). Reactions were run in 384-well 
plate under uniform cycling conditions. The cDNA templates were mixed with 
the reaction mix and equal volumes (10 μl) was loaded to each well. Cycling 
conditions were as follows: Uracil N-glycosylase (UNG) activation (50°C, 2 
min), polymerase activation (95°C for 20 sec), 40 PCR cycles (denaturation, 
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95°C for 1 sec and an annealing step performed at 60°C for 20 sec). Data 
analysis was based on the ΔΔCT method with normalization of the raw data to 
an housekeeping gene (actin). Relative quantification is used to compare the 
gene expression levels between different groups of mice and results were 
expressed as fold-changes (assuming control group average expression as 
unit). 
Hepatic fatty acid composition 
 
The analysis of liver FA composition was conducted by Dr Papasani V 
Subbaiah, at the Department of Medicine, Section of Endocrinology, Diabetes, 
and Metabolism, University of Illinois at Chicago. Levels of hepatic FA 
subspecies were measured using gas chromatography/mass spectrometry 
(GC/MS) as previously described [366].  
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3 In vitro Lipase activity assays  
Generation of EL and LPL conditioned media 
 
EL and LPL were generated using recombinant adenoviruses. Recombinant 
adenoviruses encoding either human EL (AdhEL) and human LPL (AdhLPL) 
[211]. Subconfluent COS cells were infected with recombinant adenoviruses 
in serum-free medium (3,000 particles/cell). After 48 h, heparin was added to 
a final concentration of 10 U/ml to detach lipases from the cells surface. The 
plates were incubated for an additional 30 min. The media were then 
harvested, aliquoted and frozen at −80°C. Expression of enzymes was 
confirmed by Western blotting.  
In vitro activity against a large lipid emulsion  
 
Triglyceride lipase activity was measured according to a modification of the 
method of Nilsson-Ehle and Schotz [369]. Conditioned medium containing 
LPL and EL was used as the enzyme source whereas a glycerol-stabilized 
large lipid emulsion has been used as substrate. Briefly, 300 mg triolein 
(Sigma Aldrich), 18mg egg phosphatidylcholine (Sigma Aldrich) and 3H-
Triolein (Perkin Elmer 99 μg per 300 mg nonradioactive triolein) were dried 
under nitrogen. 5 mL of glycerol (Fisher Scientific) were added and the 
mixture was sonicated using a Branson 450 microtip sonicator for five 
minutes. Concentrated emulsions were allowed to clear overnight. 15 μL of 
this concentrated emulsion was combined with 90 μL distilled water, 15 μl of 
1.0 M Tris pH 8.0, 15 μl of 15% BSA solution, and 15 μl of 3.0 M NaCl to give 
a final volume of 150 μl of working emulsions.  
Working emulsion substrate (150 μl) was combined with different dilutions of 
EL and LPL conditioned media (150 μl) or post-heparin plasma (20 μl, diluted 
1:8) were incubated at 37 °C for 30 minutes. Heat-inactivated serum was 
added to provide apoC-II for LPL reaction (0.5% of final volume). The reaction 
was terminated by the addition of 3.25 ml of methanol:chloroform:heptane 
solvent (1.41:1.25:1.00). 1.05 ml of pH 10.0 Buffer (Thermo Fisher Scientific) 
was added and tubes were spun at 2,000 RPM for 20 minutes. The upper 
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phase containing liberated fatty acids was used for scintillation counting (0.5 
ml per sample) [370]. The relative amount of hydrolysis of 3H-Triolein to 3H-
oleic acid was calculated for each sample.  
In vitro activity against labeled human TRL 
 
In this assay, increasing volumes of EL and LPL conditioned media were 
incubated with 3H-TO labeled TRL. TRL were isolated and labeled as 
previously described (see section 1). 50 uL of this substrate was incubated 
with 70 uL of enzyme containing media. For the combination assay, different 
volumes of each medium were mixed and brought to a final volume of 70 uL. 
2% weight/volume BSA was added to prevent product inhibition of the 
reaction. Mixtures wre incubated for 4 hours at 37 °C. The reaction was 
stopped by adding 1 mL of ice cold ethanol. Tubes were immediately placed 
in dry ice and kept at -20 °C overnight.  Samples were then spun 13500 
rpm/20 min to permit protein precipitation. The surnatatant, containing all lipid 
species, was transferred in glass tubes and dried down under nitrogen. Lipids 
were resuspended in 60 uL of chlorophorm and separated into the different 
species by Thin Layer Chromatography, TLC (mobile phase: Exane: diethyl 
ether: Acetic Acid (170:30:1), stationary phase: glass microfiber silica paper, 
Agilent Technologies). Samples were run together with lipid standards (cold 
Triolein, Oleate and Diacylglycerol) to identify the migration point of selected 
lipid species. The three bands were cut and counted for each condition using 
a scintillation counter. Each sample was run at least in triplicate. TG lipase 
activity was expressed as percentage of counts of the FA band compared to 
total counts (sum of activity in Triolein, Oleate and Diacylglycerol bands). 
4. Statistical Analysis  
All data are represented as mean and standard deviation, with error bars 
showing standard deviation. Statistical comparisons between two groups were 
performed using a two-tailed Student’s t-test. When required, correction for 
multiple comparison has been applied. Statistical significance was defined as 
P < 0.05 for all analyses. All the tests were run using Graph Pad Prism 
software. 
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Results  
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Specific aim 1: Establishing the effect of EL 
deficiency on the onset of clinical hallmarks of 
metabolic syndrome 
 
 
1.1 EL deficiency alters adipocyte phenotype, fat 
distribution and exacerbates diet-induced obesity 
 
In order to induce the essential traits of metabolic syndrome, three 
independent cohorts of WT and EL-KO mice (n=8) were put on high fat diet 
(45% calories from fat). Body weight and food consumption were recorded 
weekly for 12 weeks. As expected, in both groups the diet induced a 
significant increase in body mass (Figure R-1.1). EL-KO mice in all the three 
replicate experiments, displayed a significantly higher weight increase 
compared to WT (Figure R-1.1 and R1.2A) and this change was not 
accompanied by increased food intake (Figure R-1.2B).  
The NMR analysis of body composition revealed that weight increase was 
due to increased fat mass (36.98 ± 9.14g in WT and 42.46 ± 9.65g in EL-KO, 
P=0.0180) whereas the lean tissue was decreased in EL-KO mice (63.09 ± 
7.03 in WT and 56.14 ± 4.39 in KO, P=0.0415) (Figure R-1.3A). 
Traditionally, adipose tissue has been classified into white fat, mainly involved 
in lipid storage, and brown fat, that constitutively express high levels of 
thermogenic genes. Given the different metabolic and clinical significance of 
these two fat depots, the body fat composition and distribution in the two 
groups was assessed. Fat pads from WT and EL-KO mice were collected 
after 12 weeks of High Fat diet and weighted (Figure R-1.3B). No difference 
was observed in brown fat mass between WT and EL-KO mice (0.631  0.043 
and 0.648  0.052 g for WT and KO, respectively) whereas white fat mass 
was significantly increased in EL-KO mice compared to WT and this 
difference was particularly striking for the inguinal depot (subcutaneous fat- 
WT: 3.05  0.803 KO: 3.71  0.151g, inguinal fat- WT: 4.014  0.819, KO: 4.9 
 0.925 g) (Figure R-1.3B). The mass and function of visceral fat depot has 
been positively associated with the risk of developing metabolic disease. This 
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raised the hypothesis that the increased deposition of visceral fat observed in 
EL-KO mice may be accompanied by differences in the adipocyte metabolic 
and morphologic profile. To address this question, histological analysis of 
inguinal fat was performed. Samples of ~50 mg of tissue were fixed in PFA, 
paraffin-embedded, sectioned and stained with H&E (Figure R-1.4A). The 
adipose cell size and number of cell per analyzed area were determined using 
Adiposoft analysis software. The cell-size range in the collected samples was 
1000-19000 m2 (FigureR-1.5). The average adipocyte area was significantly 
higher in EL-KO mice compared to WT (WT: 175.33  10.83 KO: 294.31  
35.67 m2), indicating that visceral fat is not only hyperplasic but also 
hypertrophic in these mice (Figure R-1.4B-C). 
Given the high heterogeneity among adipose cells size, the cell-size 
distribution in the two groups was calculated. Figure R-1.5 shows the relative 
frequency of each subpopulation. Results indicate that EL-KO mice exhibit a 
reduction in small adipocyte and a parallel increase in large hypertrophic cells. 
Increase in both adipose cell size and number is a crucial process in obesity 
development and reflects changes in the adipocyte energy metabolism. In 
order to evaluate the impact of EL deficiency on the adipose tissue function 
the mRNA levels of key genes involved in fat lipid homeostasis was analyzed 
(Figure R-1.6). 
Results indicated that EL-deficiency alters the expression levels of genes 
involved in FA utilization (Figure R-1.6). Lpl, the main responsible for the 
hydrolysis of dietary-derived TG and Fabp4 a cytoplasmic chaperone involved 
in the trafficking of released FA are both significantly upregulated. Consistent 
with the increase adipocyte size, there is a trend to increase expression of 
genes responsible for lipogenesis and lipid storage and Fasn is significantly 
more expressed in EL-KO mice compared to WT. 
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Figure R-1.1 Body weight of WT and EL-KO mice pre-and after long-term 
high-fat diet.  
 
Body weights of EL WT vs. KO male mice (8 per group) prior and 12 weeks 
after the initiation of high-fat diet. Data are expressed as mean  SD. *P<0.05, 
**P<0.01, ***P<0.001, A-B: Student’s unpaired t-test.  
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Figure R-1.2. Body weight increase in WT and EL-KO mice in response to 
high fat feeding.  
 
Panel A: Weight increase in WT and KO mice.  Body weights were measured 
weekly starting at the week of initiation of the high-fat diet (week 0). Data are 
expressed as percentage of initial body weight. Panel B: Food weights from 
cages of EL WT vs. KO mice fed a 45% high-fat diet. Data represents the total 
food weight per cage, divided by the number of mice per cage. Data are 
expressed as mean  SD. *P<0.05, **P<0.01, ***P<0.001, C-D: Student’s 
unpaired t-test with correction for multiple comparison. 
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Figure R-1.3: Body composition and fat distribution in WT vs EL-KO mice. 
 
Panel A: Fat and lean mass measured by NMR in mice fed a high-fat diet for 
12 weeks. Masses are expressed as percentages of total body weight for 
each mouse. Panel B: Adipose depot mass from mice after sacrifice at 12 
weeks of feeding high-fat diet. Data are expressed as mean  SD. *P<0.05, 
Student’s unpaired t-test.  
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Figure R-1.4: Histological analysis of adipocyte morphology and cell size 
 
Panel A: Representative H&E staining of inguinal fat from WT and EL-KO 
mice fed a high-fat diet for 12 weeks. Average adipocyte area ( m2) (Panel B) 
and number of cells per area unit (Panel C) were calculated using Adiposoft 
software. Data are expressed as mean  SD. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.001 Student’s unpaired t-test 
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Figure R-1.5: Size distribution of inguinal adipocytes from WT and EL-KO 
mice on high-fat diet 
 
Adipose tissue sections from WT and KO mice were stained with H&E and the 
cell areas were determined using the Adiposoft image software. The x axis 
shows the size range of different cells subpopulations and the y axis shows 
the relative frequency of each subpopulation (mean  SD). *P<0.05, Student’s 
unpaired t-test 
 
 
Figure R-1.6: Adipocyte gene expression pattern of WT and EL-KO mice fed a 
high-fat diet for 12 weeks. 
 
Relative mRNA levels of WT and EL-KO adipocytes isolated from inguinal fat. 
Gene expression was normalized to expression of actin. Data are expressed 
as mean  SD. *P<0.05, **P<0.01, ***P<0.001, Student’s unpaired t-test.  
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1.2 EL-deficiency worsen diet-induced glucose 
intolerance  
 
In order to assess the role of EL in the modulation of glucose metabolism, a 
Glucose Tolerance Test (GTT) was performed. WT and EL-KO mice were 
fasted overnight. Fasted blood glucose levels were determined and then 10 
μl/g body weight of a 20% (w/v) glucose solution was administered 
intraperitoneally. Subsequently, the blood glucose level at 15, 30, 60, 90 and 
120 min was measured. When fed a regular chow diet, WT and EL-KO mice 
displayed a normal response to glucose load. The hematic glucose 
concentration reached the peak at 30 min after injection and progressively 
normalized. No differences were observed between the two groups in this 
setting (Figure R-1.7A). As expected, upon exposure to high fat diet, both 
groups of mice developed progressive glucose intolerance (Figure R-1.7B-C). 
However, in EL-KO mice the blood glucose concentration remained 
persistently high even in the later time points (Figure R-1.7B-C). These results 
indicate that EL deficiency may be associated with the development of an 
earlier and more pronounced glucose intolerance and may predispose to 
frank insulin resistance. To directly test the tissues response to insulin an 
intraperitoneal insulin tolerance test was performed. In this experiment, mice 
were challenged by injecting a bolus of human insulin (0.75 U/Kg of body 
weight) and blood glucose was monitored over time. Results indicated a 
modest elevation of glucose levels in EL-KO mice compared to WT, thus 
indicating that despite the progression of glucose intolerance the peripheral 
response to insulin is still preserved (Figure R-1.8).  
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Figure R-1.7: Progression of glucose intolerance in mice on high-fat diet 
 
Mice (n=10 per group) were fasted overnight and administered 10 μl/g body 
weight of 20% glucose solution intraperitoneally. Glucose was measured from 
tail blood before the beginning of experiment and at 15, 30, 60, 90 and 120 
min after injection. Panel A: EL WT vs. KO mice on chow diet. Panel B: EL 
WT vs. KO mice after 6 weeks of high-fat diet. Panel C: EL WT vs. KO mice 
after 12 weeks of high-fat diet. For each panel, results were expressed as 
glucose concentration at the indicated time-points (curve on the left) and 
respective Area Under the Curve (AUC) (bar graph on the right). Data are 
expressed as mean  SD *P<0.05, **P<0.01, Student’s unpaired t-test.  
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Figure R-1.8: Insulin Tolerance Tests in EL WT vs. KO mice fed a high-fat diet 
for 12 weeks. 
 
Intraperitoneal Insulin tolerance test (ITT) was performed by injection of 
human insulin (Humalin-R, 0.75 U/kg body weight) into WT and EL-KO mice 
(n=6) after 4 h fast. Blood samples were collected immediately before and at 
15, 30, 60, and 120 min after injection. Results were expressed as glucose 
concentration at the indicated time-points (curve on the left) and respective 
Area Under the Curve (AUC) (bar graph on the right). Data are expressed as 
mean  SD. 
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1.3 Effect of EL deficiency on systemic inflammatory 
response 
Endothelial lipase plasma levels have been associated with several markers 
of inflammation in humans [228, 334] and in vitro experiments have 
demonstrated that pro-inflammatory stimuli are able to increase EL gene and 
protein expression in different cell types [224, 371]. 
In order to determine whether absence of EL may directly or indirectly impact 
the inflammatory state associated with obesity, the inflammatory response to 
experimentally induced endotoxemia in WT and EL-KO mice was determined. 
Briefly, a low dose of Lipopolysaccharide (LPS) (0.5 mg/Kg body weight) was 
injected in both mice cohorts and the inflammatory response was monitored 
by measuring TNF  plasma concentration at different time points (0, 1 and 3 
hours after injection). EL deficiency induced a marked increase in cytokine 
levels at 3 hrs (1616.47  719.86 and 6812.60  3382.14 pg/mL TNF  in WT 
vs. EL-KO, respectively) (Figure R-1.9). This data indicated that lack of EL is 
associated with a more intense inflammatory response and this may be at 
least partially due to a more severe obese phenotype. 
 
 
Figure R-1.9: Response to experimentally induced endotoxemia 
 
Endotoxemia was induced by intraperitoneal injection of low-dose LPS (0.5 
mg/Kg body weight). Plasma was collected prior to injection and at 1 and 3 
hrs post-administration. TNF  concentration was measured by ELISA.  
Data are expressed as mean  SD ***P<0.001, Student’s unpaired t-test. 
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1.4 Energy expenditure and muscle FA utilization are 
not affected by EL deficiency  
EL-KO mice might gain more weight compared to WT as a result of impaired 
exergy expenditure. In order to test this hypothesis, basic metabolic 
parameters in WT and EL-KO mice after 8 weeks of high-fat diet, were 
measured using the comprehensive lab animal monitoring systems (CLAMS) 
at the Mouse Phenotyping, Physiology and Metabolism Core (University of 
Pennsylvania). The following parameters were then measured for 24 hours: 
oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory 
exchange ratio (RER), caloric heat production (Heat) and physical activity 
level (Total movement). No difference in any of the measured parameters was 
observed between WT and EL KO mice (Figure R-1.10).  
To better explore the energy utilization phenotype in these mice, the total 
mRNA levels of key genes involved in FA uptake and de novo lipogenesis in 
heart and skeletal muscle were measured (Figure R-1.11B-C). Furthermore, 
H&E staining of skeletal muscle sections was performed to highlight potential 
histological abnormalities and determine the presence of fat deposition 
(Figure R-1.11A).  Results indicated no difference in the gene expression 
levels of myocytes and cardiomyocytes between WT and EL-KO mice. 
Consistent with this gene expression pattern, the histological findings from 
skeletal muscle samples were comparable (Figure R-1.11).  
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Figure R-1.10: Metabolic phenotyping of WT and EL KO mice  
 
WT and EL-KO mice were monitored for basic metabolic parameters using 
the Comprehensive Lab Animal Monitoring System (CLAMS) at the Mouse 
Phenotyping, Physiology and Metabolism Core (University of Pennsylvania). 
The following parameters were measured for 24 hours: oxygen consumption 
(VO2, Panel A), carbon dioxide production (VCO2, panel B), respiratory 
exchange ratio (RER, Panel C), caloric heat production (Heat, Panel D) and 
activity level (Total movement, Panel E). 
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Figure R-1.11: Skeletal muscle and heart gene expression pattern  
 
Panel A: Representative H&E staining of skeletal muscle from WT and EL-KO 
mice fed with high-fat diet for 12 weeks. Panel B: Relative mRNA levels of WT 
and EL-KO myocytes (n=6 per group). Panel C: Relative mRNA levels of WT 
and EL-KO cardiomyocytes. Gene expression was normalized to expression 
of actin. Data are expressed as mean  SD. Student’s unpaired t-test.  
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Specific Aim 2: Defining the role of EL in plasma 
TG-rich lipoprotein metabolism 
2.1 EL-KO mice display increased TC, PL, HDL and 
non-HDL-C on low-fat diet 
In order to study the role of EL in TG-rich lipoprotein metabolism, an extensive 
characterization of the plasma lipoprotein profile of WT and EL-deficient mice 
in response to a high fat diet was performed. Fasted plasma lipids from adult 
WT and EL-KO mice (n=8) on regular chow diet were measured before the 
initiation of the diet. Consistent with previously published data, absence of EL 
induced a significant increase in total cholesterol and phospholipids and this 
was due to an increase in both HDL-C and non-HDL-C plasma levels (Figure 
R-2.1A and Table R-1)[213, 216]. No differences in TG and non-esterified 
fatty acids were observed between WT and EL-KO mice in these conditions 
(Figure R-2.1A-B and Table R-1). 
 
Figure R-2.1: Plasma lipid profile of WT and EL-KO mice on regular chow diet 
 
Panel A: Plasma lipids concentrations Panel B: Plasma Non-Esterified Fatty 
Acids (NEFA). Plasma from adult male mice (n=8) was collected after 4 hours 
fasting. All measurements were performed using an autoanalyzer. Data are 
expressed as mean  SD *P<0.05, ***P<0.001, Student’s unpaired t-test. 
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2.2 EL-deficiency is associated with a more severe 
diet-induced dyslipidemia and markedly affects TG 
plasma levels 
In order to assess whether EL deficiency may affect the development of diet-
induced dyslipidemia, serial measurements of plasma lipids during the high-
fat diet treatment were done. In both strains all the measured parameters 
progressively increased with time on diet and they were overall higher in EL-
KO mice (Table R-1 and Figure R-2.2A-F). However, the calculation of the 
percentage of change compared to baseline levels for each parameter 
indicated that non-HDL cholesterol, NEFA and phospholipids increased at the 
same rate in WT and EL-KO mice (Table R-1 and Figure R-2.2B, E-G). On 
contrary, TC levels increased at a lower rate in EL-KO mice and that was 
explained by a significant reduction in HDL-C (Table R-1 and Figure R-2.2A, 
B, G). Finally, TG concentration, that was comparable between the two 
groups at the baseline, was dramatically higher in EL-KO mice at 12 weeks 
(Table R-1 and Figure R-2.2D, G).  
 
 
Chow diet 
4 weeks on 
high-fat diet 
12 weeks on 
high-fat diet 
Mean SD Mean SD Mean SD 
TC  
(mg/dL) 
WT 93.2 5.7 149.4 19.7 168.7 27.0 
EL-KO 153.1 23.6 201.5 43.6 220.2 43.1 
HDL-C 
(mg/dL) 
WT 66.8 6.5 102.9 18.0 126.3 16.4 
EL-KO 102.3 19.2 138.9 29.3 146.7 27.6 
Non-HDL-C 
(mg/dL) 
WT 26.4 2.9 46.6 11.2 42.4 13.1 
EL-KO 50.8 8.6 63.5 16.0 76.7 16.3 
TG  
(mg/dL) 
WT 43.4 21.5 35.7 9.8 90.2 56.6 
EL-KO 37.0 13.7 38.7 9.1 146.8 90.0 
NEFA 
(meq/L) 
WT 0.6 0.1 0.7 0.2 0.8 0.2 
EL-KO 0.6 0.2 0.8 0.2 0.9 0.1 
PL  
(mg/dL) 
WT 160.0 45.1 266.5 25.6 289.4 35.4 
EL-KO 235.3 67.7 343.9 54.7 335.8 48.8 
 
Table R-1: Plasma lipid profile of WT and EL-KO before and after 4 and 12 
weeks on high-fat diet. 
 
Results and statistically different findings are shown in figure R-2.2. 
 
 99 
 
Figure R-2.2: Plasma lipid profile of WT and EL-KO mice before and after 4 
and 12 weeks on high-fat diet. 
 
Panels A-F: Plasma lipids were measured on day 0, at 4, and 12 weeks of 
initiation of the high-fat diet. Each lipid measurement was performed on 
plasma collected after a 4 hour fasting, using an autoanalyzer. Panel A: Total 
Cholesterol. Panel B: HDL-Cholesterol. Panel C: Non-HDL Cholesterol. Panel 
D: Triglycerides. Panel E: Non-Esterified Fatty Acids (NEFA). Panel F: 
Phospholipids.  
Panel G: Relative change in 4 hour fasting plasma lipids on week 12 vs. 
baseline (Day 0) of the high fat diet. Data are expressed as mean  SD 
*P<0.05, **P<0.01, ***P<0.001, Student’s unpaired t-test. 
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2.3 The analysis of fasted and fed plasma lipid profile 
in EL-KO mice reveals diet-induced abnormalities in 
lipoprotein remodeling 
The initial characterization of plasma lipids demonstrated that the dietary 
intervention was able to exacerbate the dyslipidemic phenotype in EL-
deficient mice. To further investigate the nature of this association, we 
evaluated the plasma lipoprotein profile in the fasted versus fed state. To this 
purpose, the same pool of WT or EL-KO mice was bled twice (both the 
collections were performed at week 8 on diet). The first collection was 
performed after 4 hour fasting. Mice were then re-fed and the second 
collection was performed the following day. During this time, mice were fed ad 
libitum. Plasma from each group of mice was pooled and lipoproteins were 
fractionated using Fast Protein Liquid Chromatography (FPLC).  Eluted 
fractions were then tested for cholesterol and triglyceride content. The 
apolipoprotein expression in selected fractions was assessed by western blot.   
Long-term high-fat feeding profoundly affected cholesterol and TG profiles in 
both WT and EL-KO mice (figures R-2.3-5). Nevertheless, the two strains 
responded very differently to fasting-refeeding. In fasting conditions WT mice 
displayed very little TG content compared to EL-KO mice and it was almost 
equally eluted in VLDL-CM and LDL regions (peak concentration= 6.67 g/mL 
and 4.80 g/mL, respectively, figure R-2.3A). Upon re-feeding, TG levels 
increased dramatically in both peaks (15.40 g/mL and 14.21 g/mL in VLDL-
CM and LDL peaks, respectively figure R-2.4A). TG-enrichment in the CM 
peak was consistent with post-prandial lipid loading and the coexistence of a 
TG-rich peak in the LDL region indicated a further remodeling of CMs into 
IDL-LDL.  
In EL-KO mice, the fasted plasma TG content was extremely high in both 
peaks (17.42 g/mL and 22.82 g/mL in VLDL-CM and LDL peaks, 
respectively, figure R-2.3A). Notably, the VLDL-CM peak concentration in KO 
mice in fasted condition was comparable to what observed in WT mice in the 
fed state (figure R-2.5). In the postprandial state this peak was further 
enriched in TG (24.92 g/mL), whereas the IDL-LDL peak did not change 
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(22.50 g/mL, figure R-2.4A). WB analyses of apolipoproteins in these 
fractions revealed a relatively higher apoB-48 content in EL-KO mice both in 
fasted and fed conditions (figure R- 2.3 and 2.4A). 
The analysis of the cholesterol profile in fasted WT mice was consistent with 
the effects of a long-term high-fat diet and revealed the presence of major 
cholesterol-enriched HDL peak and a smaller LDL shoulder (figure R-2.3B). 
This profile was only minimally affected by re-feeding (figure R-2.4B).  
In fasted EL-KO mice, the amount of cholesterol eluted in the LDL region was 
significantly higher than in WT and it became even higher upon refeeding. 
Interestingly, lipoproteins eluted in this region were significantly more enriched 
in apoE and apoB-100 ( figure R-2.3B and 2.4B). 
Taken altogether these data are supportive of an impaired remodeling of TG-
rich lipoproteins in EL-KO mice defect seems to be exacerbated by feeding.   
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Figure R-2.3: FPLC analysis of fasted plasma lipoproteins from WT and EL-
KO mice after 8 weeks of high-fat diet 
 
Triglycerides (Panel A) and Cholesterol (Panel B) from pool of 4 hours fasted 
plasma were fractionated by fast-protein liquid chromatography (FPLC) to 
separate lipoproteins. Triglycerides and cholesterol were measured by 
colorimetric plate assays. 100 μl of plasma per pool were used for FPLC 
fractionation. Selected fractions were then analyzed by SDS-page 
electrophoresis to separate proteins and immunoblotted against apoB (panel 
A) and apoE (Panel B). 
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Figure R-2.4: FPLC analysis of fed plasma lipoproteins from WT and EL-KO 
mice after 8 weeks of high-fat diet 
 
Triglycerides (Panel A) and Cholesterol (Panel B) from pool of 4 plasma from 
mice fed ad libitum were fractionated by fast-protein liquid chromatography 
(FPLC) to separate lipoproteins. Triglycerides and cholesterol were measured 
by colorimetric plate assays. 100 μl of plasma per pool were used for FPLC 
fractionation. Selected fractions were then analyzed by SDS-page 
electrophoresis to separate proteins and immunoblotted against apoB (panel 
A) and apoE (Panel B). 
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Figure R-2.5: Overlapping FPLC profile of fed and fasted plasma lipoproteins 
from WT and EL-KO mice after 8 weeks of high-fat diet 
 
Cholesterol (Panel A) and Triglycerides (Panel B) FPLC profiles shown in 
Figures R2.3 and R2.4 were plotted together in order to better highlight the 
changes occurring in the postprandial state. 
 
 
 
 
A
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2.4 EL deficiency delays postprandial TG-rich 
lipoprotein clearance 
 
The observation that EL-KO mice displayed an abnormal lipid and lipoprotein 
profile and that this phenotype became more severe in the fed state, 
prompted to the direct investigation of the effect of EL deficiency on 
postprandial TG-rich lipoprotein clearance. To this purpose, an Oral Fat 
Tolerance Test (OFTT) was performed on two separate cohorts of WT and 
EL-KO mice on regular low and high-fat diet.  Briefly, WT and EL KO mice 
were gavaged with olive oil (10 ul/g of body weight) and plasma was collected 
at different time points to permit TG measurements (0-1-3-5 and 7 hours post 
gavage). Results from this experiment are summarized in Table R-2. WT mice 
displayed a normal TG clearance profile in either low or high-fat feeding 
conditions (figure R-2.6A,B and C, Table R-2). The TG concentration reached 
the maximum peak at 3 hours post-gavage and it completely normalized at 7 
hours (figure R-2.6A,B and C, Table R-2). In contrast, we observed that loss 
of EL markedly affected TG clearance. In EL-KO mice on chow diet, TG 
plasma levels significantly increased upon olive oil gavage at 1, 3, 5 and 7 
hours and they were still double the baseline at this latter time-point (Figure 
R-2.6A). This alteration was even more dramatic after 10 weeks of high fat 
diet. In these conditions, EL-KO mice displayed persistently high 
triglyceridemia with virtually no clearance by 7 hours (Figure R-2.6 B and C).  
These results were supportive of a markedly impaired post-prandial TG-rich 
lipoprotein clearance that resulted in severe plasma TG accumulation. In 
order to discern the nature of the accumulated TG-rich lipoproteins, two 
different qualitative analyses were performed on plasma from the OFTT 
experiment. WT and EL-KO samples from the 7 hours time-point were pooled 
and an FPLC fractionation of plasma lipoproteins was performed. TG, 
cholesterol and apoB content of eluted fractions was determined using 
colorimetric assay and WB. In WT mice, 7 hours after gavage the lipoprotein 
profile was completely normalized and showed very little residual TG in the 
CM-VLDL region and non-detectable apoB (Figure R-2.7A and C). The 
cholesterol profile indicated a major HDL peak accompanied by a smaller LDL 
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shoulder (Figure R-2.7B). Conversely, the analysis of TG profile in EL-KO 
mice revealed a massive accumulation of TG in the CM-VLDL region (+223% 
of WT) and a minor peak in the LDL region (Figure R-2.7A). The analysis of 
cholesterol profile confirmed this data and showed a substantial TC 
enrichment of lipoproteins eluted in the CM-VLDL and LDL regions, 
accompanied by a parallel reduction of cholesterol in HDL fractions (Figure R-
2.7B). When analyzed by WB, the CM-VLDL fractions from EL-KO mice 
appeared to be enriched in apoB-100 and apoB-48. Notably, the 
densitometric analysis of the bands indicated that the apoB-48: apoB-100 
ratio was on average 3.1. Although in mice apoB-48 can be synthetized by 
both liver and intestine, the relatively higher abundance of this protein 
compared to apoB100 was suggestive of the presence of CM remnants 
(Figure R-2.7C).  
In addition, plasma samples collected at different time-points of the OFTT 
experiment were analyzed by agarose-gel electrophoretic analysis. This 
technique separates plasma lipoproteins by charge/size and permit to 
discriminate between CM (non-migrating) and other apoB-containing 
lipoproteins (  and pre-  migrating). Results from this experiment are shown 
in figure R-2.8. Before the beginning of the experiment, mice were fasted 
overnight. As expected, in this condition no chylomicrons were detected in WT 
and EL-KO mice (Figure R-2.8, O hrs). 3 hours post-gavage the TG 
concentration reached the maximum peak (figure R-2.6C). This was evidently 
represented in the EF analysis and translated in the presence of a major CM 
band at the origin of the gel (Figure R-2.8, 3 hrs). Notably, the CM band was 
significantly more intense in EL-KO mice compared to WT and it was still 
persistent at 7 hours after gavage (Figure R-2.8, 3 and 7 hrs).   
In summary, loss of EL markedly delayed chylomicron and VLDL-TG 
clearance and resulted in high levels of circulating triglyceride-rich particles.  
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Time-point 
(hrs) 
Chow diet 
TG (mg/dL) 
High-fat diet 
TG (mg/dL) 
WT KO WT KO 
Mean SD Mean SD Mean SD Mean SD 
0 112.31 21.22 109.27 57.45 129.17 37.86 181.45 57.78 
1 144.39 61.34 252.00 63.49 319.47 140.61 294.75 118.22 
3 293.66 101.21 906.62 718.60 415.20 214.46 1445.26 569.49 
5 269.11 175.55 863.20 740.02 267.25 140.35 1078.08 698.19 
7 226.03 153.77 376.59 306.16 158.22 84.14 1218.02 979.51 
 
Table R-2: Response to Oral Fat Tolerance Test in WT and EL-KO mice on 
chow and high-fat diet 
 
Figure R-2.6: Oral fat Tolerance Test (OFTT) in EL WT vs. KO mice fed a 
chow diet and high-fat diet for 10 weeks. 
 
Postprandial plasma triglycerides in EL WT vs. KO mice fed a chow (Panel A-
B) or high fat diet (Panel B), following oral gavage with olive oil. Mice (6 per 
group) were fasted overnight, and gavaged with 10 μl/g body weight of oil 
olive. Plasma was collected at the indicated time-points. Plasma TG were 
measured by colorimetric plate assays. Panel C: Tubes containing plasma 
from the 7-hour time point following olive oil gavage from mice on high-fat 
diet. Data are expressed as mean  SD *P<0.05, **P<0.01, ***P<0.001, 
Student’s unpaired t-test 
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Figure R-2.7: FPLC profile of plasma lipoproteins from WT and EL-KO mice 7 
hours post olive oil gavage 
 
Plasma from WT and EL-KO mice was collected 7 hours post gavage of olive 
oil, pooled and fractionated into lipoproteins using FPLC. Triglycerides (Panel 
A) and cholesterol (Panel B) were measured by colorimetric plate assays. 
Panel C: Western blot analysis of apoB content of fractions 4-11 (VLDL-CM 
peak). 
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Figure R-2.8: Agarose-gel electrophoresis of plasma lipoproteins from WT 
and EL-KO mice at 0,3 and 7 hours after gavage 
 
Plasma from WT and EL-KO mice was collected before and at 3 and 7 hours 
post gavage of olive oil, pooled and separated by charge/size using agarose 
gel electrophoresis. Lipoproteins were detected by Fat Red neutral lipid 
staining. Red boxes highlight the chylomicron region (origin of electrophoretic 
migration). 
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2.5 Evaluation of potential mechanisms responsible 
for increased TG-rich lipoprotein accumulation  
Collectively, results from the previous experiments indicated that EL-
deficiency was associated with impaired post-prandial TG clearance. The 
further investigation of potential mechanisms responsible for the observed 
phenotype was done by directly assessing TG-rich lipoprotein catabolism. 
When endogenous and dietary TG enter the circulation via VLDL and CM, 
they are readily hydrolyzed by plasma lipases and released FA are taken up 
by peripheral cells. This process is very rapid and it’s believed to be mainly 
driven by LPL activity. 
The impact of EL deficiency on TG-rich lipoprotein lipolysis was evaluated 
through in vivo kinetic experiments. TG-rich lipoproteins from non-fasted 
human plasma were isolated by density-gradient ultracentrifugation (d<1.006) 
and labeled with 3H-triolein. WT and EL-KO mice on high fat diet for 12 weeks 
were then intravenously injected with the substrate and plasma was serially 
collected to determine the activity decay. In order to selectively investigate the 
lipolytic-driven lipoprotein catabolism and minimize the contribution of further 
lipoprotein remodeling, the experiment was terminated at 15 min after 
injection and animals were sacrificed. The analysis of plasma 3H-triolein 
activity revealed that the removal of TG-derived FA from the circulation was 
slower in EL-deficient mice (figure R-2.9A). Residual 3H activity was 
significantly higher in EL-KO mice at all the indicated time points (figure R-
2.9A) and that translated in a significantly reduced Fractional Catabolic Rate 
(FCR) (figure R-2.9A).  
To examine whether enhanced clearance of triglycerides was also due to 
enhanced particle uptake by peripheral tissues, the same experiment was 
repeated using 125I-labeled lipoproteins (Figure R-2.9B). In this setting, 125I 
turnover was considered a marker for whole particle clearance. No difference 
was observed in 125I clearance between WT and EL-KO mice (Figure R-2.9B).  
Finally, to assess whether EL-deficiency could possibly affect the hepatic 
VLDL-TG secretion, WT and EL deficient mice were injected with Pluronic to 
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inhibit endogenous lipolysis. TG accumulation at different time-points (0, 1, 2, 
and 4 hours after injection) was measured with colorimetric assay and the TG 
production rate was calculated. EL-KO mice showed a trend-to decrease in 
TG production that was more evident in the later time-points. However, this 
difference didn’t translate into a significantly different production rate (Figure 
R-2.10). 
Results from these three experiments collectively lead to the conclusion that 
in EL-deficient mice, TG accumulation was due to impaired TG clearance 
from the circulation and this was mainly explained by impaired lipolysis rather 
than to impaired particle uptake. 
 
Figure R-2.9: Plasma clearance of 3H-triolein and 125I labeled human TG-rich 
lipoproteins in EL WT vs. KO mice fed a high-fat diet for 12 weeks. 
 
Human lipoproteins were isolated by density gradient ultracentrifugation 
(d<1.006 g/mL) and labeled with 3H-triolein or 125I. They were then injected 
intravenously and mice were bled for plasma activity measurements at the 
indicated time-points. The experiment was terminated 15 min after injection.  
Panel A: 3H oleate plasma clearance and Fractional Catabolic Rate (FCR) 
Panel B: 125I-protein plasma clearance and Fractional Catabolic Rate (FCR). 
Data are expressed as mean  SD *P<0.05, **P<0.01, ***P<0.001, 
****P<0.000. Student’s unpaired t-test. 
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Figure R-2.10: TG secretion rate in WT vs. EL-KO mice fed a high-fat diet for 
12 weeks. 
 
WT and EL-KO mice (10 per group) were fasted for 4 hours and 
intraperitoneally injected with the detergent Pluronic to inhibit lipolysis. Plasma 
was collected serially 1, 2, and 4 hours after Pluronic injection and TG 
concentration was measured with a colorimetric assay. Panel A: plasma TG 
concentration at indicated time points. Panel B: Calculated VLDL-TG 
secretion rate. Data are expressed as mean  SD *P<0.05. Student’s 
unpaired t-test. 
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2.6 Impact of EL deficiency on expression and activity 
of other extracellular lipases 
The observation that EL-deficient mice displayed severely impaired TG-
lipolysis raised the question whether the observed effect was due to a direct, 
previously underappreciated, activity of EL towards TG or to an indirect effect 
of EL on other extracellular lipases. This question has been addressed 
through two different strategies.  
The first set of experiments was designed to test the ability of EL and LPL to 
hydrolyze TG on a synthetic substrate containing 3H-triolein. This assay 
allows one to determine TG activity independently of the endogenous 
substrate. To test the specific affinity of EL and LPL towards TG, media 
containing each enzyme were obtained by adenoviral-mediated gene transfer 
in COS-7 cells. Increasing volumes of EL and LPL-media were incubated with 
a 3H-triolein labeled emulsion substrate and liberated fatty acids were 
quantified by scintillation counting. Consistent with previously published data, 
LPL exhibited a significantly higher TG activity compared to EL (Figure R-
2.11).  
The TG lipase potential of WT and EL-deficient plasma was assessed 
according to a similar experimental approach. Post heparin plasma from WT 
and EL-KO mice was incubated with 3H-triolein labeled synthetic substrate 
and TG lipase activity was quantified as previously described. Results 
indicated that EL deficiency did not affect post-heparin plasma (PHP) TG 
lipase activity (Figure R-2.12A). Since LPL is believed to be the main 
responsible for TG lipolysis in plasma, the total expression of this protein has 
been assessed by WB. No difference was observed between the two 
experimental groups (Figure R-2.12B). 
These results demonstrated that PHP from EL-KO mice retained the ability to 
hydrolyze TG and that was likely due to an intact LPL functionality. However, 
these data were in contrast with the in vivo observation that EL-deficient mice 
had a significantly impaired post-prandial lipolytic activity.  
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In order to test whether EL deficiency impaired TG clearance by altering LPL 
interaction with the substrate, a second set of experiments was designed. In 
these experiments, increasing volumes of EL and a constant volume of LPL 
conditioned media were incubated with human 3H-triolein-labeled-TG-rich 
lipoproteins. After incubation, lipids were extracted, separated by Thin Layer 
Chromatography (TLC) and the percentage of released FA was quantified by 
scintillation counting. Results indicated that EL had very little activity on 
isolated TG-rich lipoproteins compared to LPL (figure R-2.13A). Surprisingly, 
when EL and LPL were co-incubated, the experimentally measured TG lipase 
activity was significantly higher than what expected by summing the 
contributions (figure R-2.13B).  
 
 
 
 
Figure R-2.11: TG-lipase activity of EL and LPL conditioned media towards 
synthetic substrate 
 
Media containing EL or LPL were obtained by adenoviral-mediated 
transfection of COS-7 cells . The media were then used as source of enzyme 
for further activity assays. Increasing volumes of EL and LPL-media were 
incubated with a 3H-triolein labeled emulsion substrate. Products of reaction 
were extracted and the liberated fatty acids (FFAs) were quantitated by 
scintillation counting. Panel A: Volume/TG-lipase activity plot  
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Figure R-2.12 TG-lipase activity of post-heparin plasma from WT and EL-KO 
mice 
 
Panel A: Post heparin plasma TG-lipase activity in WT and EL-KO mice (8 per 
group) was measured by incubating the samples with a 3H-triolein emulsion 
substrate. The products of reaction were extracted and the liberated fatty 
acids (FFAs) were quantitated by scintillation counting. Panel B: western blot 
analysis of post heparin plasma from WT and KO mice showing LPL protein 
levels.  
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Figure R-2.13: Single ad combined TG-lipase activity of EL and LPL towards 
human TG-rich lipoproteins. 
 
Media containing EL or LPL were obtained by adenoviral-mediated 
transfection of COS-7 cells. Human TG-rich lipoproteins were isolated from 
human plasma by density-gradient ultracentrifugation and labeled with 3H-
triolein. This substrate was used to determine the TG-lipase activity of LPL 
and EL alone or in combination. Products of reaction were extracted and lipids 
were separated with Thin Layer Chromatography (TLC) and counted. Results 
are expressed as % Free Fatty Acids activity vs. Total activity. Panel A: TG-
lipase activity of a fixed volume of LPL, Increasing volumes of EL and co-
incubation of the two enzymes. For the co-incubation assay a constant 
volume of LPL and increasing volumes of EL were added to the reaction mix. 
Panel B: Direct comparison between experimentally measured and calculated 
(sum of single contributions) TG-lipase activity of media containing both EL 
and LPL at different volume ratios. Data are expressed as mean  SD 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Student’s unpaired t-test with 
adjustment for multiple comparison. 
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Specific Aim 3: Defining the impact of EL 
deficiency on liver lipid metabolism. 
3.1 EL deficiency is associated with increased hepatic 
steatosis 
EL is physiologically expressed in adult liver and may contribute to hepatic 
lipid sensing and regulation of hepatic lipid storage. Absence of EL can thus 
potentially alter hepatic lipid homeostasis and lead to abnormal fat deposition. 
To test this hypothesis livers from WT and EL-KO mice on high fat diet for 12 
weeks were collected, weighted and processed for H&E and Oil Red O 
staining.  Liver weight was significantly higher in EL-KO mice compared to WT 
(1.6 ± 0.04 and 1.9 ± 0.16 g, in WT and KO mice, respectively n=6) and the 
overall appearance was consistent with the development of steatosis. The 
histological analysis confirmed that EL deficient mice were subjected to a 
significantly higher neutral lipid deposition (figure R-3.1A) and highlighted the 
presence of all the morphologic features of steatosis. To confirm these 
findings, liver tissues from WT and EL-KO mice were homogenized and lipids 
were solubilized using sodium deoxycholate. Tissue TG and cholesterol levels 
were then determined using a colorimetric assay. The analysis confirmed that 
the hepatic lipid content was significantly higher in EL-KO mice compared to 
WT (figure R-3.1B). 
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Figure R-3.1 Hepatic lipid accumulation in WT vs. EL-KO mice. 
 
Panel A: Histological analysis of livers from WT and EL-KO mice after 12 
weeks of high fat diet. In order to detect lipid depot, H&E staining (left) and Oil 
Red O staining of neutral lipids (right) were performed. Panel B: Hepatic 
triglycerides (left) and cholesterol (right) from the same mice. Liver 
homogenates from mice were solubilized using sodium deoxycholate and 
lipids were measured by colorimetric plate assay. Data are expressed as 
mean  SD *P<0.05, **P<0.01, ***P<0.001, Student’s unpaired t-test 
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3.2 Defining the mechanisms involved in increased 
hepatic lipid accumulation in EL-deficient mice 
 
In animal models, excess in dietary-derived TG translates in obesity and this 
condition is often associated with steatosis. Prolonged high-fat feeding, in 
fact, leads to the release of high concentrations of FA into the portal 
circulation. FA can be taken up by the liver via hepatic fatty acid translocase 
[372]. This process is upregulated during obesity-induced inflammation. 
Cytokines upregulate the expression of FA transporters at the hepatocyte 
membrane and further enhance the flux of FA entering the liver.  
EL-KO mice develop a significantly more severe obesity, hypertriglyceridemia 
and reactive inflammatory response. In order to test whether this phenotype 
could contribute to hepatic steatosis, human 3H-TG-labeled lipoproteins were 
prepared as previously described and they were injected in WT and KO-mice. 
The experiment was terminated 15 minutes after injection and mice were 
sacrificed to permit tissue collection. The 3H activity in each tissue, was 
considered as representative of the total TG tissue uptake. Surprisingly, 
despite the increased TG plasma levels and the markedly more severe 
obesity, hepatic FA uptake was significantly impaired in EL-deficient mice 
(figure R-3.2). Since EL and HL, but not LPL are physiologically expressed in 
the adult mouse liver, it has been hypothesized that EL-deficiency could 
impair the hydrolysis of TG at the hepatic endothelial surface thus negatively 
impacting FA uptake. To address this question, we measured the gene and 
protein expression levels of HL and LPL. Results indicated a significant 
increase in LPL gene and protein levels in EL-KO compared to WT whereas 
HL expression was comparable in the two groups (figure R-3.3).   
Since EL is believed to have a higher specificity for HDL-derived PL 
compared to TG, and PL-derived FA can modulate liver function, a similar 
experiment has been conducted using a synthetic PL-labeled substrate. In 
this experiment, fluorescently labeled palmitoyl-PC (TopFluorPC) was used to 
synthetize reconstituted liposomes (diameter 12nm), that were injected in WT 
and EL-KO mice on chow diet. Since the HDL turnover requires a longer time 
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compared to TG-rich lipoprotein lipolysis, mice were sacrificed at 6 hours after 
injection and tissues were collected.  Similar to what observed in the 3H-TG-
labeled lipoproteins, we observed a significantly reduced PC-derived FA 
uptake in the liver of EL-KO mice (figure R-3.4) 
To address whether increased TG accumulation was a result of de novo 
lipogenesis, the expression levels of key genes involved in the regulation liver 
lipid metabolism was tested. Results indicated an overall upregulation of 
lipogenic genes in EL-KO mice compared to WT and significantly increased 
SCD1 protein levels (figure R-3.5).  
Thanks to a collaboration with PV Subbaiah, at the University of Illinois, we 
were able to further explore this hypothesis. The analysis of liver FA in WT 
and EL-KO mice showed that the dietary intervention lead to significant 
changes in the total FA mass and distribution in both groups. On chow diet, 
WT and KO mice displayed a comparable liver FA content (41.16 9.21 and 
43.26  5.62 g/mg of tissue, in WT and KO respectively). However, EL-KO 
mice had a 1.6 times higher response to high fat-feeding, that resulted in 
significantly higher FA mass at 12 weeks on diet (138.44 28.91 and 232.89  
55.13 g/mg of tissue, in WT and KO respectively). The relative abundance of 
FA species was also deeply affected by the diet (Table R-3,R4). The 
percentages of most of the saturated fatty acids decreased (16:0, 18:0, 20:0, 
22;0), as well as the percentage of some selected polyunsaturated FA (20:4 
and 22:6) (Table R-3,R4 figure R-3.6) . This was compensated by a significant 
increase in 14:0, 16:1, 18:1, 20:1 and 22:5. These changes were more 
pronounced in EL-KO mice compared to WT (Table R-3,R4 figure R-3.6). The 
ratios of 18:1/18:0, 16:1/16:0, that are considered indicators of SCD activity, 
were disproportionately increased in KO livers compared to WT, thus 
supporting the idea that EL deficient mice may have increased hepatic de 
novo lipogenesis (18:1/18:0 WT=1.52 on chow diet and 9.14 on high fat diet; 
18:1/18:0 KO= 1.47 on chow diet and 15.10 on high-fat diet; 16:1/16:0 WT= 
0.07 on chow diet and 0.19 on high fat diet; 16:1/16:0 KO=0.08 on chow diet 
and 0.13 on high-fat diet). 
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Figure R-3.2 3H oleate tissue uptake. 
Human lipoproteins were isolated by density gradient ultracentrifugation 
(d<1.006 g/mL) and labeled with 3H-triolein. They were then injected 
intravenously in WT and EL-KO mice. Animals were sacrificed 15 min after 
injection for tissues collection. Data are expressed as mean  SD *P<0.05, 
Student’s unpaired t-test.  
 
 
 
Figure R-3.3 Hepatic LPL and HL gene and protein expression in EL WT vs. 
KO mice fed a high-fat diet for 12 weeks.  
 
Panel A: Hepatic LPL gene (left) and protein (right) expression in EL WT vs. 
KO mice fed a high-fat diet for 12 weeks. Panel B: Hepatic HL gene (left) and 
protein (right) expression in EL WT vs. KO mice fed a high-fat diet for 12 
weeks. Gene and protein expression were normalized to expression of actin. 
Data are expressed as mean  SD *P<0.05, Student’s unpaired t-test 
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Figure R-3.4 TopFluor-PC tissue uptake. 
WT and EL-KO mice (n=6) were intravenously injected with synthetic 
liposomes containing TopFluor-PC and they were sacrificed 6h after injection 
for tissue collection. The fluorescence intensity is expressed as RLU/mg 
tissue (mean  SD). *P<0.05, **P<0.01, Student’s unpaired t-test.  
 
 
 
Figure R-3.5 Hepatic gene and protein expression in EL WT vs. KO mice fed 
a high-fat diet for 12 weeks.  
 
Panel A: Hepatic gene expression in EL WT vs. KO mice fed a high-fat diet for 
12 weeks. Gene expression was normalized to expression of actin. Panel B: 
Total hepatic immunoblots of LPL and SCD1 from the same mice. Data are 
expressed as mean  SD *P<0.05, **P<0.01, Student’s unpaired t-test. 
 
 
 123 
 
 
Figure R-3.6 Lipidomic analysis of Hepatic Fatty Acid content of mice on chow 
vs. high fat diet 
 
Total fatty acid composition of WT and EL-KO livers was determined by 
GC/MS. The plots show the % of each FA species vs. total FA of WT and EL-
KO mice on chow diet (Panel A) and after 12 weeks on high-fat diet (Panel B) 
Data are expressed as mean  SD. For each dietary condition, the relative % 
of FA species has been compared for WT vs. EL-KO mice. For clarity, single 
data and significant results are reported in Table R-3 (chow diet) and R4 (high 
fat diet).  
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FA 
species 
WT KO 
Difference SE  
Adjusted 
P Value % of 
Total FA 
SD 
% of 
total FA 
SD 
12:0 0.30 0.61 0.05 0.02 -0.24 0.27 0.9978 
14:0 0.76 0.82 0.36 0.06 -0.40 0.37 0.9959 
16:0 26.17 1.43 26.39 0.90 0.22 0.75 0.9996 
16:1 1.96 0.33 1.84 0.23 -0.12 0.18 0.9985 
17:1 0.19 0.39 0.06 0.04 -0.13 0.18 0.9985 
18:0 11.70 2.50 11.72 1.03 0.02 1.21 0.9996 
18:1  
(n-9) 
15.15 2.19 14.76 1.18 -0.39 1.11 0.9996 
18:1 
(n-7) 
2.00 0.44 1.86 0.19 -0.14 0.21 0.9985 
18:2 20.41 3.57 19.57 1.27 -0.84 1.70 0.9991 
18:3  
(n-6) 
0.65 0.55 0.44 0.17 -0.21 0.26 0.9985 
18:3 
 (n-3) 
0.71 0.35 0.69 0.12 -0.03 0.16 0.9996 
20:0 0.29 0.07 0.48 0.04 0.19 0.04 0.0239 
20:1  
(n-9) 
0.45 0.07 0.54 0.05 0.09 0.04 0.7076 
20:2 0.28 0.07 0.37 0.14 0.09 0.07 0.9933 
20:3 1.44 0.72 1.35 0.10 -0.09 0.33 0.9996 
20:4 5.79 0.62 6.72 0.75 0.93 0.43 0.7378 
22:0 0.28 0.30 0.14 0.09 -0.14 0.14 0.9959 
20:5 1.66 0.45 1.59 0.15 -0.07 0.21 0.9996 
22:2 0.08 0.05 0.16 0.13 0.08 0.06 0.9947 
22:4  
(n-6) 
0.35 0.58 0.07 0.05 -0.28 0.26 0.9959 
22:5 0.96 0.35 1.29 0.54 0.33 0.29 0.9959 
22:6 8.20 0.70 9.47 0.72 1.28 0.45 0.3858 
24:1 0.20 0.17 0.07 0.04 -0.12 0.08 0.9485 
 
 
 
Table R-3: GC/MS analysis of Hepatic FA content of WT and KO mice on 
chow diet. 
 
Relative % of each FA species/total FA content (mean and SD) in WT (n=8) 
and EL-KO mice (n=5) on chow diet. The three columns on the right show the 
results from the statistical comparison of the relative FA abundance in the two 
strains (Multiple t-test with significance assessed with Holm-Sidak method, 
with alpha = 0.05). Significant results (p<0.05) are highlighted in grey. 
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FA 
species 
WT KO 
Difference 
SE of 
difference 
Adjusted 
P Value % of 
Total FA 
SD 
% of 
total FA 
SD 
12:0 0.01 0.01 0.01 0.00 0.00 0.00 0.9484 
14:0 0.58 0.05 0.72 0.05 0.14 0.03 0.0154 
16:0 26.10 0.85 24.41 0.45 -1.70 0.42 0.0324 
16:1 3.41 0.26 4.64 0.49 1.23 0.21 0.0021 
17:1 0.01 0.01 0.00 0.01 -0.01 0.01 0.7377 
18:0 4.49 0.69 3.08 0.45 -1.40 0.35 0.0354 
18:1  
(n-9) 
36.54 2.20 40.87 1.98 4.33 1.21 0.0627 
18:1 
(n-7) 
3.52 0.42 4.27 0.26 0.75 0.21 0.0627 
18:2 14.76 1.25 14.20 0.39 -0.55 0.58 0.9484 
18:3  
(n-6) 
0.34 0.04 0.34 0.02 0.00 0.02 0.9975 
18:3  
(n-3) 
0.41 0.08 0.40 0.01 -0.01 0.04 0.9975 
20:0 0.29 0.05 0.23 0.08 -0.06 0.04 0.7812 
20:1  
(n-9) 
1.08 0.06 1.24 0.04 0.16 0.03 0.0037 
20:2 0.20 0.21 0.37 0.02 0.16 0.09 0.7377 
20:3 1.03 0.10 0.82 0.10 -0.21 0.06 0.0466 
20:4 4.29 0.74 2.30 0.42 -1.99 0.37 0.0042 
22:0 0.07 0.04 0.06 0.03 -0.01 0.02 0.9897 
20:5 0.11 0.10 0.11 0.06 -0.01 0.05 0.9975 
22:2 0.05 0.05 0.09 0.03 0.03 0.03 0.8684 
22:4  
(n-6) 
0.35 0.28 0.31 0.17 -0.04 0.14 0.9975 
22:5 0.13 0.20 0.30 0.07 0.18 0.10 0.6699 
22:6 2.21 0.33 1.23 0.12 -0.98 0.16 0.0015 
24:1 0.02 0.01 0.01 0.00 -0.01 0.01 0.2656 
 
 
 
Table R-4: GC/MS analysis of Hepatic FA content of WT and EL-KO mice 
after 12 weeks on high-fat diet  
 
Relative % of each FA species/total FA content (mean and SD) in WT and EL-
KO mice on high-fat diet for 12 weeks (n=5 per group). The three columns on 
the right show the results from the statistical comparison of the relative FA 
abundance in the two strains (Multiple t-test with significance assessed with 
Holm-Sidak method, with alpha = 0.05). Significant results (p<0.05) are 
highlighted in grey. 
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Discussion 
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Endothelial lipase (EL) is a major determinant of HDL-C levels [89, 90, 218]. 
Given the established inverse correlation between HDL-C and cardiovascular 
disease, early human studies have focused on investigating the relationship 
between EL activity, pro-atherogenic lipid profile and CVD risk. Most of the 
studies that directly measured EL mass or activity were conducted in 
populations of individuals with traits of metabolic syndrome [228, 330, 373]. At 
the time of the studies several pieces of evidence had already demonstrated 
that EL activity was inversely correlated to HDL-C levels and its expression 
was positively regulated by inflammation [89, 224, 228, 334]. Metabolic 
syndrome was thus an ideal model to assess whether EL could affect the 
development of CVD by reducing plasma levels of atheroprotective HDL. 
These studies consistently demonstrated a strong correlation between EL 
mass and several traits of metabolic syndrome such as body mass index 
(BMI), visceral adiposity, inflammation, insulin resistance and atherogenic 
lipoprotein levels [228, 229, 330]. However, the directionality of the 
association is still not known and whether EL mass or activity could drive the 
progression of one or multiple of the indicated traits it’s not clear. 
Furthermore, although LIPG genetic variants are associated with increased 
HDL-C levels in humans, their association with the risk of CVD has not been 
convincingly supported (table 4).  
First objective of this thesis was to establish the effect of EL deficiency on the 
onset of clinical hallmarks of metabolic syndrome. In mice, most of the traits of 
metabolic syndrome can be induced by high-fat feeding. When EL-deficient 
mice were kept at low-fat (chow) diet, their body weight was comparable to 
that of WT. Surprisingly, on high-fat diet EL-deficiency was associated with 
significantly increased weight gain. The analysis of body composition 
highlighted the presence of increased fat mass and decreased lean mass. 
The fat accumulation was more pronounced in the epididymal region and the 
analysis of the fat morphology revealed that it was due to an increased 
number and size of adipocytes. The relatively higher weight gain was not 
explained by increased food intake or decreased energy expenditure, thus 
suggesting a dysfunctional utilization of FA. The mechanism underlying these 
abnormalities has not been fully elucidated but the expression analysis of 
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genes involved in intracellular FA trafficking and de novo lipogenesis revealed 
an upregulation of these pathways in adipose tissues with no major changes 
in heart and skeletal muscle. Notably adipocyte LPL mRNA levels were 
significantly increased in EL-KO mice compared to WT. It has been 
demonstrated that in murine lipoprotein-deficient adipose tissue, endothelial 
lipase represents an alternative pathway for FFA uptake [357]. Data from this 
study support this hypothesis and suggest that in absence of EL, LPL may be 
subjected to a compensatory upregulation.  
Abnormalities in glucose metabolism and low-grade inflammation are features 
commonly associated with obesity and represent peculiar traits of metabolic 
syndrome [374]. These conditions are intimately related. High fat feeding 
induces constitutively high TG plasma levels. Adipose tissue is an insulin 
sensitive compartment and responds to calories in excess by storing FA in the 
form of TG. This process induces adipocyte hypertrophy and predispose to 
cell dysplasia and subsequent increased macrophage infiltration. At the same 
time, hypertrophic adipocytes are characterized by a hyperlipolytic state that 
is resistant to the antilipolytic effect of insulin. This condition further increases 
the FA flux to the liver and impairs liver glucose and fat metabolism [374]. The 
efficiency of glucose metabolism in WT and EL-KO mice was assessed by 
measuring the glucose tolerance (defined as clearance of an intraperitoneal 
glucose load) and insulin tolerance (glucose response to an intraperitoneal 
injection of insulin). On low-fat diet, EL-deficient mice displayed a normal 
response to glucose loading but progressively developed a pre-diabetic 
phenotype when fed hypercaloric diet. At 12 weeks, EL-KO mice showed a 
frank glucose intolerance whereas insulin sensitivity was preserved. Similarly, 
high fat-feeding seemed to induce a metainflammatory status in EL-KO mice. 
At the baseline both groups of mice had similar levels of TNF , but when they 
were exposed to a pro-inflammatory stimulus, EL-KO mice displayed a 
significantly higher inflammatory response. In humans there is a strong 
correlation between plasma levels of EL and cytokines in obese and healthy 
individuals. It has been proposed that obesity, in particular visceral adiposity 
may be sufficient to induce and sustain EL upregulation in individuals with 
metabolic syndrome. Data from this study show that in a high-fat dietary 
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setting, absence of EL is associated with earlier and a more severe obesity. 
Furthermore, the onset of the different traits suggests that, in this model, 
obesity may be a primary event in the development of metabolic syndrome 
whereas glucose intolerance and low-grade inflammation seem to be 
secondary. Taken altogether these observations support the hypothesis that 
increased EL expression may be a physiological compensatory mechanism in 
response to diet-induced metabolic abnormalities rather than a causal factor. 
One of the main characteristics of the metabolic syndrome is dyslipidemia, 
characterized by increased cholesterol and TG levels, and reduced HDL-C 
levels. Previously published studies widely demonstrated that EL mediates 
HDL catabolism by promoting PL hydrolysis. Furthermore, EL can promote 
the clearance of apoB-containing lipoproteins and this process is dependent 
on its hydrolytic activity [211, 216, 222]. Very little is known about the role of 
EL in TG-rich lipoprotein metabolism. LPL is thought to be the main 
responsible for the catabolism of TG-rich lipoproteins but isolated reports 
suggest that in certain conditions EL-mediated hydrolysis may represent an 
alternative pathway to release FA in peripheral tissues [2, 357, 375]. The 
second aim of this thesis was thus to determine the role of EL in plasma TG-
rich lipoprotein metabolism. This aspect has been extensively elucidated in 
this study by characterizing the lipid profile of WT and EL-deficient mice in 
response to a high fat diet. Consistent with previous reports, in this study we 
found that on low-fat dietary setting, EL deficiency is associated with 
increased cholesterol and PL plasma levels and this effect is explained by a 
significant increase in both HDL and non-HDL-C levels [356]. As expected, 
the high-fat dietary intervention induced significant changes in plasma lipids in 
both WT and EL-deficient mice and all the measured lipid parameters were 
significantly increased after 12 weeks. However, although the levels of FA, 
PL, and non-HDL cholesterol increased at a similar rate in both strains, HDL-
C increased at a relatively lower rate in EL-KO mice. Finally, TG plasma 
levels seemed to be the most severely affected by the dietary treatment, 
showing a two-fold higher change compared to WT. Since there was no 
difference between WT and KO mice at the baseline, it can be deduced that 
the latter change was triggered by the prolonged dietary intervention. Given 
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the enzymatic properties of EL, we hypothesized that EL-deficiency may 
directly or indirectly impair the TG-rich lipoprotein remodeling and that this 
condition may become more evident upon a chronic high-TG dietary 
supplementation. Further analyses were then specifically aimed to 
characterize the features of plasma lipoproteins in WT versus EL-deficient 
mice in response to the chronic high-fat feeding and to detect the remodeling 
efficiency in the transition between fasted and fed state. The FPLC 
fractionation revealed that EL-KO mice displayed a significantly higher 
cholesterol and TG-enrichment of apoB-containing lipoproteins and these 
changes became even more dramatic upon re-feeding. The apoB-48 and 
apoB-100 content was also significantly higher in EL-deficient mice, thus 
suggesting a parallel increase in the number of particles and a possible 
retention of post-prandial CM remnants. This possibility has been directly 
tested by performing an oral-fat tolerance test, followed by qualitative 
analyses of plasma lipoproteins (FPLC and agarose gel electrophoresis). 
Results demonstrated that EL-deficiency is associated with persistent post-
prandial hyperlipemia and that is due to the accumulation of apoB-100 and 
apoB-48-containing lipoproteins, at least in part identifiable as chylomicrons. 
Notably, this trait was already detectable in mice on chow diet, thus 
suggesting that it may be a pre-existing feature directly associated with EL 
deficiency and not secondary to other causes. In this scenario, the chronical 
administration of high fat diet may exacerbate an already pre-existing 
phenotype. Different mechanisms can concur to the retention of post-prandial 
TG-rich lipoprotein remnants. Physiologically, a key event in CM and VLDL 
clearance, is lipase-mediated hydrolysis. The efficiency of this process in WT 
and EL-KO mice was specifically tested through an in vivo kinetic experiment 
where WT and EL-KO mice were injected with either protein and TG-labeled 
TG-rich lipoproteins and their clearance was evaluated over 15 minutes. 
Results indicated that EL deficiency was associated with significantly impaired 
3H-TG clearance whereas the 125I-protein clearance was not affected. 
Together these findings indicate that, in this experimental setting, the impaired 
clearance is primarily attributable to a reduction of TG lipolysis and not to an 
impaired particle uptake by peripheral tissues. Another mechanism that can 
contribute to TG-rich lipoprotein accumulation is hepatic production of VLDL. 
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We then measured the hepatic production of VLDL-TG by pharmacologically 
inhibiting plasma lipases and then measuring the plasma TG accumulation 
over time. Results show that EL-KO mice displayed a moderate trend to 
decreased TG production, thus indicating that hepatic VLDL secretion is not a 
major contributor to plasma TG levels in EL-deficient mice. The potential 
biochemical causes underlying the observed phenotype were then explored 
by testing EL and LPL lipase activity in vitro. Consistent with previously 
published data, EL and LPL displayed a different activity towards a synthetic 
3H-TG-labeled VLDL-like emulsion [211]. Although EL was capable of an 
appreciable dose-dependent TG lipase activity, the quantitative relevance of 
this reaction was significantly lower compared to LPL. However, the activity of 
plasma lipases can be modulated by several inhibitors in vivo and different 
lipases can exert cooperative effects on the same substrate. The post-heparin 
plasma activity assay represents a useful tool to evaluate the potential 
influence of these different factors on the TG-lipase activity and has been 
widely used in several animal and human studies. In this study, we didn’t 
observe any difference in the post-heparin plasma activity of EL-KO and WT 
mice. However, when we co-incubated different ratios of EL and LPL with 3H-
TG-labeled isolated VLDL, we observed that the resulting activity was higher 
than what expected by calculating the sum of the contributions. These results 
support the conclusion that EL may modulate plasma TG levels by facilitating 
LPL activity in a synergistic fashion. This effect seems to be dose-dependent 
and requires the presence of a lipoprotein substrate. Furthermore, since EL 
does not display a significant TG activity on isolated lipoproteins per se, the 
observed effect is likely a consequence of its phospholipase activity. The 
overall effect of this synergistic activity in vivo is difficult to predict. Lipases are 
synthetized by different cell types and they are then secreted in the vascular 
space where they bind to heparan sulfate proteoglycans. As a result, different 
lipases coexist on the endothelial wall and it is possible that this spatial 
proximity may also translate in a functionally complementary activity. 
Supporting this concept, in healthy subjects, simultaneous heterozygosity for 
SNPs in different lipase genes (EL 2,237 3 untranslated region, EL Thr111Ile, 
HL 514C/T, and LPL HindIII) had synergistic association with plasma TG, 
beyond individual gene effects [376].  
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Increased adiposity, glucose intolerance and hypertriglyceridemia are 
associated with an increased risk of developing fatty liver disease in humans 
[221]. The phenotype observed in EL-KO mice fed a high-fat diet recapitulates 
all these pro-steatotic conditions. Therefore, the third objective of this study 
was to define the impact of EL deficiency on liver FA metabolism. When 
compared to WT, EL-deficient mice showed a significantly more pronounced 
steatosis. The uptake of 3H-TG-derived FA by the liver was 50% decreased, 
and this was accompanied by the upregulation of lipogenic genes. The 
lipidomic analysis of hepatic FA content confirmed these findings and showed 
not only a significantly increased fat content in the livers of EL-deficient mice 
but also a disproportionately higher increase in monounsaturated fatty acid. 
The 18:1/18:0 and 16:1/16:0 ratios were in fact 1.7 and 1.5 folds higher in EL-
KO mice compared to WT. These indexes are established markers of SCD1 
activity, the enzyme that catalyzes the limiting step of monounsaturated fatty 
acid synthesis and are positively correlated with triglyceride generation. 
Notably, LPL gene and protein were both significantly more expressed in EL-
KO mice, whereas HL levels were comparable. This finding was unexpected 
because hepatic LPL expression levels are physiologically high during 
embryogenesis but they progressively drop after birth and they are negligible 
in adult animals. Once again, these findings are supportive of a model where 
different lipases cooperate in the metabolism of circulating lipoproteins and 
suggest a potentially previously underappreciated crosstalk in the expression 
of EL and LPL. Whether this mutual influence in the regulation of expression 
is representative of partially overlapping function is not known and further 
studies will be required to address this point. However, according to the 
present data hepatic LPL upregulation is not sufficient to normalize the 
hepatic FA uptake.  
In conclusion, the current thesis work demonstrated that EL deficiency in the 
high-fat dietary setting is associated with the development of earlier and more 
severe traits of metabolic syndrome, namely obesity, visceral adiposity, 
glucose intolerance and metainflammatory status. Furthermore, deficiency of 
EL in mice results in significantly impaired lipolytic catabolism of TG-rich 
particles and this effect seems to be mediated by an indirect impairment of 
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LPL activity. Finally, these changes result in a subsequent decreased delivery 
of TG-derived FA to the liver and a parallel upregulation of lipogenic 
pathways. 
Collectively these data support a model by which EL is required for efficient 
triglyceride-rich lipoprotein clearance and the absence of this function impairs 
hepatic fat intake and results in compensatory de novo lipogenesis, which 
may contribute to systemic obesity and insulin resistance (figure C-1). 
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Figure C-1: Proposed model of EL deficiency-induced abnormalities in 
plasma, liver and adipose tissue metabolism. 
 
Panel A: EL hydrolyzes TG and surface PL in TRL. This process facilitates the 
further hydrolysis of TG by LPL. Released FA can be taken up by liver and 
adipose tissue through specific transporters. Panel B: in absence of EL, LPL 
has access to a limited amount of TG. This impairs the availability of FA to 
adipose tissue and liver. This is associated with hepatic upregulation of LPL, 
lipid transporters and lipogenic genes and translates into increased de novo 
lipogenesis, steatosis and insulin resistance. In the adipose tissue, lack of EL 
induces increased expression of membrane lipid transporters and lipogenic 
genes. This leads to increased lipid storage and predispose to inflammation. 
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